СПЕЦИФИЧЕСКИЙ ДЛЯ ПАЦИЕНТА ИММУНОАДСОРБЕНТ ДЛЯ ЭКСТРАКОРПОРАЛЬНОГО АФЕРЕЗА И СПОСОБ ЕГО ПОЛУЧЕНИЯ

Изобретение может быть использовано в медицине для лечения аутоиммунных заболеваний. Заявлен иммуноадсорбент для экстракорпорального афереза, специфический для каждого пациента. Он состоит из антигенов и антител, ковалентно связанных с активированным биосовместимым твердым материалом-носителем. Антигены и антитела получены путем расщепления иммунокомплексов, изолированных из крови или других жидкостей тела того же самого пациента, для которого данный иммуноадсорбент предназначен. Способ получения иммуноадсорбента включает выделение иммунокомплексов из крови и/или других жидкостей тела пациента, очистку их и расщепление на антитела и антигены и ковалентное связывание их с активированным биосовместимым материалом-носителем. Изобретение позволяет лечить хронические формы аутоиммунных заболеваний и заболеваний, связанных с дизрегулированием иммунной системы. При этом исключается опасность передачи возбудителей таких заболеваний, как ВИЧ и гепатит. 2 с. и 5 з.п. ф-лы, 7 ил., 7 табл.

СПОСОБ И УСТРОЙСТВО ДЛЯ ОЧИСТКИ КРОВИ ОТ ЦИРКУЛИРУЮЩЕЙ ВНЕКЛЕТОЧНОЙ ДНК

Tumour necrosis factor-alpha and/or bacterial lipo-poly:saccharide removal

Extracorporeal removal of tumour necrosis factor- alpha (TNF- alpha ) and/'or bacterial lipopolysaccharides (LPS, endotoxin) from whole blood and/or blood plasma is carried out with a perfusion system contg. cationic and anionic exchange material. Also claimed is a device based on this technique for the treatment of patient blood and/or plasma and which is capable of simultaneous removal of TNF- alpha and LPS is described.

Hochwirksame Abtrennung von lipoproteinischem Cholesterol niedriger Dichte aus Vollblut

Verfahren zur simultanen Entfernung von Tumor-Nekrose-Faktor „ und bakteriellen Lipopolysacchariden aus einer wäßrigen Flüssigkeit

GERÄT FÜR DIE PLASMAREINIGUNG IN KOMBINATION MIT PLASMAADSORPTION-PERFUSION DURCH VERWENDUNG EINES TRIKOMPARTIMENT-DIALYSATORS

BLOOD PLASMA TREATING METHOD

METHOD AND APPARATUS FOR THE TREATMENT OF AUTOIMMUNE AND ALLERGIC DISEASES

Transdermal bioreactor

APHERESE-VORRICHTUNG

APHERESE-VORRICHTUNG

KIT FOR THE TREATMENT OF ILLNESSES IN CONNECTION WITH SYSTEMIC INFLAMMATIONS

DIALYSAT REGENERATIONSEINHEIT

MECHANISM FOR BLOOD CLEANING

PROCEDURE AND DEVICE FOR THE INDIRECT OXIDATION OF UREA.

PROCEDURE FOR SIMULTANEOUS EXTRAKORPORALEN THE ELIMINATION OF TUMOR NECROSIS FACTOR ALPHA AND BACTERIAL ONE LIPOPOLYSACCHARIDEN FROM FULL BLOOD AND/OR BLOOD PLASMA

PROCEDURE FOR THE QUANTITATIVE SELECTIVE DISTANCE OR PRÄPERATIVEN PRODUCTION OF TUMOR NECROSIS FACTOR (TNF) AND LIPOPOLYSACCHARIDEN (LPS) FROM AQUEOUS LIQUIDS

DIAPHRAGM AFFINITY SYSTEM AND PROCEDURE FOR ITS USE

Immunoadsorption

Upon administration of r AAV vectors the humoral immune response (neutralizing antibodies) is the first barrier that needs to be overcome. Surprisingly it was found that by using immunoadsorptionfor depletion of immunoglobulinsfrom the blood (plasma), subjects can be highly efficiently treated with rAAV vectors, i.e. obtain highly efficient transduction after rAAV vector administration, in spite of the presence of high levels of nAb.

Reduction of advanced glycation endproducts from bodily fluids

The invention concerns removing advanced glycation end products from a bodily fluid by contacting the bodily fluid with a sorbent.

Method and device for purification of blood from circulating cell free DNA

The invention provides apheresis devices and their use for removal of substantially all types of cell free DNA (cfDNA) in patients' blood, including nucleosome -bound cfDNA, exosomebound cfDNA and unbound cfDNA (including double stranded DNA (dsDNA), single stranded DNA (ssDNA) and oligonucleotides), to limit the negative effects of the circulating cfDNA and to treat various diseases.

Treatment of tumors by selective protein depletion

A method of treating and preventing infectious diseases

Medicament and apparatus for treating chronic kidney disease

The present invention provides a novel therapy concept based on a removal of circulation BSP (bone sialoprotein) from the plasma of patients with chronic kidney disease (CKD), preferably by plasmapheresis or an administration of antibodies against BSP in plasma. The present invention further provides a BSP absorber material for plasmapheresis and a pharmaceutical composition namely in form of anti-BSP antibodies for direct administration which are biocompatible in humans. The beneficial effects of this therapy have been proven by the observed correspondence between levels of circulating free BSP levels and mortality of CKD patients.

A method of treating and preventing infectious diseases

Gas treatment delivery systems and methods

The present disclosure provides apparatuses and systems for delivering a measureable absorbed-dose of a gaseous activating agent to a fluid including a biological liquid and/or cells. The apparatuses or systems include a gas-fluid contact device configured to controllably rotate or oscillate a control member having an interior surface in contact with the fluid and a control system configured to control rotation or oscillation of the contact member by the gas-fluid contact device. In some embodiments, the control system is further configured to control absorption of the gaseous activating agent by the fluid. The present disclosure also provides methods of treating a fluid including a biological liquid or cells with a gaseous activating agent to controllably activate the fluid.

PURIIFYING BLOOD AND PLASMA

Immunoadsorber for use in sepsis therapy

APPARATUS FOR PURIFYING BLOOD

... of the invention An apparatus for purifying blood which is able to separate blood into plasma and blood rich in blood cells, to purify the separated plasma and to mix the purified plasma into the blood stream simultaneously by itself. The apparatus has a simple structure without the pump for circulating plasma, the plasma path and the like, and can be operated by using only the pump for circulating blood to give a purified blood without any specific cares and difficulty. The apparatus is able to largely reduce complicated and troublesome operations required for controlling the pressure during separation of blood.

BLOOD PLASMA TREATING METHOD AND APPARATUS

... 9204-87 Treating blood by separating plasma from other blood components, adding a precipitating agent for precipitating plasma components to the plasma to form a precipitate, removing the precipitate from the plasma, removing the precipitating agent from the plasma, and mixing the other blood components with the treated plasma.

APPARATUS FOR BLOOD TREATMENT

An apparatus for blood treatment has a housing having a blood inlet for introducing the blood to be treated and a blood outlet for exhausting the treated blood, at least one blood channel within the housing and extending from the inlet to the outlet and being constituted by a plasma-separating membrane capable of allowing the plasma component of blood to permeate therethrough while preventing the blood cells from penetrating therethrough. A blood treating material is packed in the space within the housing around the blood channel. A pump is connected to the inlet for pumping blood into the inlet. A pressure varying mechanism operatively associated with the housing imposes from outside the housing on the space within the housing pressure changes for alternately changing the direction of the pressure difference between the inside of the blood channel and the blood treating material-containing space, so that the plasma component of the blood flow in the blood channel is caused to permeate ...

APPARATUS FOR PURIFYING BLOOD

... of the invention An apparatus for purifying blood which is able to separate blood into plasma and blood rich in blood cells, to purify the separated plasma and to mix the purified plasma into the blood stream simultaneously by itself. The apparatus has two parts, i.e. a blood flowing system in which the blood is separated by means of porous hollow fibers provided in a container and the purified plasma is mixed into the blood stream through the hollow fibers, and a plasma flowing path in which the separated plasma is circulated and purified at a plasma purifying device provided on the way of the path. The apparatus has a simple structure and can be operated without any specific cares and difficulty. The apparatus is free from any problems, for instance, hemolysis, fiber blockage, mixing of the purifier particles into blood, and the like.

ELECTRODIALYSIS APPARATUS AND PROCESS FOR FRACTIONATING PROTEIN MIXTURES

Apparatus and process for the fractionation of liquid solutions of protein mixtures which includes the steps of subjecting such solutions to electrodialysis (ED) while in the pH range of about between 5-6 until a partial or a substantially complete desalting takes place, the ED preferably being conducted between about 15.degree.C to 40.degree.C. separating the fraction of protein which precipitates, passing the resulting supernatant salt depleted protein mixture into the concentrating compartments of the ED apparatus whereby the salts entering the salt concentrating chambers from the adjacent salt diluting chambers will substantially restore the original salt content of the desalted protein mixture.

SYSTEM AND METHOD FOR CONTROLLING AND MONITORING BLOOD OR BIOLOGIC FLUID FLOW

A system and method are disclosed for controlling blood flow or flow of biologic fluid in an artificial organ or extracorporeal blood circuit. Selected parameters relating to blood flow are sensed and used to automatically optimize blood flow while assuring proper and safe operation. Utilized in conjunction with a reciprocating dialyzer apparatus, the system controls blood flow into and out of the dialyzer apparatus by controlling pressure on a slurry around the dialyzer membrane package. Slurry pressure is controlled by an actuator, such as a bellows pump, the pumping action of which is controlled by an electric motor, which motor, in turn, is electrically controlled by a control unit which receives sensed indicators of blood flow, pressure and/or motor current. Blood contamination is also monitored for assuring safe operation of the dialyzer apparatus.

ANTIGEN-SPECIFIC REMOVAL OF CIRCULATING IMMUNE COMPLEXES

Extracorporeal perfusion using an immunoadsorbent material specific for disease-related antigens is used for therapy of the disease state. Antibodies to particular antigens, including tumor antigens, viral antigens, and bacterial antigens, are used to prepare the immunoadsorbent material. Patients suffering from the disease are then treated by removing a flow of blood, separating the blood into plasma cellular components, passing the plasma through the immunoadsorbent material, recombining the treated plasma and cellular components of the blood, and returning the treated blood to the patient.

CONTINUOUS REMOVING SYSTEM OF BLOOD SUBSTANCES BY EXTRA CORPOREAL CIRCULATION

IMMUNOADSORPTION

Upon administration of r AAV vectors the humoral immune response (neutralizing antibodies) is the first barrier that needs to be overcome. Surprisingly it was found that by using immunoadsorptionfor depletion of immunoglobulinsfrom the blood (plasma), subjects can be highly efficiently treated with rAAV vectors, i.e. obtain highly efficient transduction after rAAV vector administration, in spite of the presence of high levels of nAb.

ADSORBING MATERIAL FOR MULTIPLE PATHOGENIC FACTORS OF SEPSIS AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF

An adsorbing material for multiple pathogenic factors of sepsis as well as a preparation method and an application thereof. The adsorbing material is formed by coupling a carrier with good mechanical performance and blood compatibility and a ligand with the capacity to adsorb multiple pathogen associated molecules, is capable of effectively adsorbing bacterial endotoxin, bacterial genome DNA, peptidoglycan, teichoic acid, virus RNA, and zymosan from fluids such as blood and the like, and in particular has application value in blood purification treatment of sepsis.

APHERESIS DEVICE

The invention relates to an apharesis device for use in the treatment of Alzheimer patients. Said device comprises a solid support with which a flow of blood or plasma can be contacted.

DIALYSIS MACHINE WITH ARTERIAL PRESSURE MONITORING BY MEASURING OXYGEN SATURATION

A dialysis machine comprising a haemodialysis filter, an input branch of the dialysing solution into said filter, an output branch of the dialysing solution from the filter, an arterial line which is responsible for conveying the blood from the patient to the filter, a venous line which is responsible for conveying the blood from the filter to the patient, and a plurality of pumps adapted to circulate both the blood and the dialysing solution, an oxygen saturation measuring device applied to the arterial line, and a command/control unit adapted to receive information from the oxygen saturation measuring device and to control other devices of the machine in order to avoid possible cardiovascular failure.

LIVER SUPPORT SYSTEM

The present disclosure relates to an artificial, extracorporeal system for liver replacement and/or assistance, comprising a liver dialysis device for conducting hemodialysis on a patient suffering from liver failure, which is characterized in that it comprises a first standard hollow fiber membrane dialyzer which does not allow passage of an essential amount of albumin over the membrane wall and which is perfused with the patient's blood, and a second hollow fiber membrane dialyzer which allows the passage of essential but defined amounts of albumin over the membrane wall and which receives the blood of the first standard hemodialyzer and wherein the filtrate space is closed off from the lumen space of the hollow fibers and is populated by adsorbent material which may comprise one or more different adsorbents.

EXTRACORPOREAL BLOOD CIRCULATOR

An extracorporeal blood circulator introducing blood collected from a body using a blood pump, subjecting a harmful substance contained in the collected blood to a predetermined treatment, and returning the thus treated blood to the body, wherein electrodes of a conductivity meter used for monitoring the treatment are arranged on an outer surface of the extracorporeal blood circulator so as to be replaceable. The electrodes can be attached and detached with ease and disinfecting time and the number of process steps can be curtailed by arranging the electrode portion of the conductivity meter on an outer surface of the circulator.

Device for the continuous, extracorporal separation of specific substances from blood

ALPHA CHAIN OF THE HIGH-AFFINITY IGE RECEPTOR (FCERIA)

PROCEDE ET DISPOSITIF POUR L'EPURATION DU SANG

INVENTION CONCERNANT L'EPURATION DU SANG. PROCEDE ET DISPOSITIF POUR L'EPURATION DU SANG SUR LA BASE DE LA COMBINAISON D'UNE HEMODIALYSE AVEC UNE HEMOFILTRATION. LE FILTRAT EXTRAIT DE L' "HEMOFILTRE" EST AMENE A UN SYSTEME D'ADSORPTION, Y EST REGENERE ET EST RAMENE EN CIRCULATION CYCLIQUE A L'HEMOFILTRE, DE SORTE QUE DANS CE DISPOSITIF LE SANG EST "DIALYSE" PAR RAPPORT A SON PROPRE FILTRAT REGENERE. APPLICATION A LA REALISATION DE REINS ARTIFICIELS.

Extracorporeal blood treatment device, has treatment unit with fluid inlet and fluid outlet, where inlet is in fluid communication with outlet of exchanger, and outlet is in fluid communication with inlet line

L'objet de la présente invention est la filtration de sang afin de séparer et extraire sélectivement des molécules de taille choisie par le biais de systèmes extracorporels pour la séparation de substances. Ainsi l'invention concerne un dispositif de traitement extracorporel de sang comprenant: au moins un échangeur (1) comportant au moins une première entrée (2) pour le sang à traiter, une première sortie (4) de fluide et une deuxième sortie (5) de fluide, une ligne d'entrée (10) du sang à traiter raccordée à la première entrée (2) de l'échangeur (1), une ligne de sortie (ou ligne veineuse) (11) du sang raccordée à la première sortie (4) de l'échangeur (1),au moins une unité de traitement (21) comportant au moins une première entrée (22) de fluide et au moins une première sortie (24) de fluide, la deuxième sortie (5) de l'échangeur (1) étant en communication de fluide avec la première entrée (22) de l'unité de traitement (21),caractérisé en ce que la première sortie (24) de l'unité de ...

DEVICE AND PROCESS OF TREATMENT OF BLOOD WITH SELECTIVE EXTRACTION OF AQUEOUS SOLUTIONS

DEVICE AND PROCESS OF TREATMENT OF BLOOD WITH SELECTIVE EXTRACTION OF AQUEOUS SOLUTIONS

DEVICE AND PROCESS OF TREATMENT OF BLOOD WITH SELECTIVE EXTRACTION OF AQUEOUS SOLUTIONS

DEVICE AND PROCESS OF TREATMENT OF BLOOD WITH SELECTIVE EXTRACTION OF AQUEOUS SOLUTIONS

BIOARTIFICIAL LIVER

This document provides bioartificial liver (BAL) devices. Methods for making and using BAL devices also are provided.

METHOD TO INHIBIT PROLIFERATION AND GROWTH OF METASTASES

The present invention provides a method to reduce the amount of undesired growth factors in the circulating blood of a subject to prevent tumor growth and proliferation during or after a wound healing and/or other local tissue repair process on a subject, comprising extracorporeal adsorption of growth factors from blood of the subject and return of the treated blood to the subject.

DEVICE FOR REMOVING PROTEIN-BOUND TOXINS FROM BLOOD PLASMA

The invention relates to a device for the extracorporeal removal of protein-bound toxins from blood plasma comprising: a first (10), second (12), third (24) and fourth (27) line device; a dialyser or haemofilter (18) and/or an adsorber (19) located between the first (10) and the second (12) line device; a means for generating a field (14), said means at least partially surrounding the first line device (10) and/or the dialyser or haemofilter (18) and/or the adsorber (19); a controllable fluid transport device (16) located in the first (10) and/or second (12) line device and at least one controllable body fluid transport device (16) located in the third (24) and/or fourth (27) line device; a filter (20), the permeate side of the filter (20) being connected to the first (10) and the second (12) line device, the inlet (22) on the dialysis side of the filter (20) being connected to the third line device (24) which can be connected to a patient (P), and the outlet (26) on said dialysis side ...

APPARATUS FOR THE EXTRACORPOREAL REMOVAL OF PROTEIN-BOUND TOXINS

The present invention relates to an apparatus for the extracorporeal removal of protein-bound toxins from blood comprising at least one blood purification apparatus, in particular at least one dialysis machine, hemofilter or adsorber, as well as at least one means for generating a field in the blood purification apparatus and/or in an element in flow communication with the blood purification apparatus, in particular in a line section connected to the blood purification apparatus, wherein the means comprises at least two strip conductors which are arranged on at least two preferably oppositely disposed sides of the blood purification apparatus or of the element such that the field is preferably predominantly generated within the blood purification apparatus or preferably predominantly within the element.

Carbon block/filtration bed/conical reactor with fluidized bed system allowing small sorbent particles to regenerate fluid during extracorporeal blood treatment

Methods and devices for powdered sorbent regeneration of biologic fluids are disclosed. The present invention includes three novel methods, which may be used singly or in any combination, for constraining or immobilizing powders so that they can be perfused with a biological fluid or dialysate: a porous carbon block filter, a filtration bed of very fine powder, and a cone-shaped reactor.

Prevention and treatment of atherosclerosis by reducing carbamylation of LDL or the effects of carbamylated LDL

The present invention provides a method of determining whether an individual is at risk for atherosclerosis, comprising the step of measuring the level of cLDL and/or autoantibody to cLDL in a sample obtained from this individual. The invention further discloses a method of reducing carbamylation in an individual with a monomeric amino acid or other enzymatic or non-enzymatic inhibitors of carbamylation. The instant invention also provides a method to decrease the level of cLDL by direct elimination of cLDL from the blood or plasma of an individual. The invention also provides a method of treating or preventing atherosclerosis in an individual by inhibiting aggregation and/or deposition of cLDL in the individual.

Method for treating patients suffering from immune thrombocytopenic purpura

Immune thrombocytopenic purpura is treated by removal of IgG and circulating immune complexes from the patient's blood. Removal is accomplished by exposing the blood or blood plasma to an immunoadsorbent capable of removing IgG and its complexes. The immunoadsorbent comprises a suitable solid phase coupled to a receptor capable of binding IgG and its complexes, such as protein A. The IgG and its complexes are then removed by the extracorporeal exposure of the patient's blood to the immunoadsorbent, either in a continuous or discontinuous process. In the continuous process, the blood is removed in a steady flow from the patient, separated into its plasma and cellular components, the plasma treated, and the combined cellular components and treated plasma reinfused to the patient. In the discontinuous method, a small volume of blood is removed from the patient, the entire volume separated into plasma and cellular components, the plasma treated, and the entire volume of treated plasma returned ...

Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases

Extracorporeal affinity adsorption treatments which are aimed at the substantial removal of two or more compounds that are etiological in the pathogenesis of diseases in man provide effective therapeutic intervention means for these diseases. The methods are particularly suitable for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases. Extracorporeal chelation and immunotherapy for atherosclerosis, extracorporeal chelation treatment with on-line regeneration or replacement of chelant, extracorporeal immunotherapy with antibody fragments, and extracorporeal immunoadsorption utilizing antibodies bound to Protein A are also disclosed.

Methods and compositions for reducing immune response

The present invention provides an apparatus and method to diminish the pre-existing immune response to the administration of a therapeutic virus by the selective elimination of antiviral antibodies from the serum. The present invention provides a chromatographic material for the elimination of such antibodies. The invention further provides plasmapheresis apparatus comprising this material. The invention further provides methods for the employment of such apparatus as part of therapeutic treatment regiments.

METHOD FOR REMOVING CYTOKINES FROM BLOOD WITH SURFACE IMMOBILIZED POLYSACCHARIDES

The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.

DIALYSIS SYSTEM INCLUDING CASSETTE WITH PUMPING TUBES

A hemodialysis system includes a blood treatment machine, a blood pump housed by the blood treatment machine, a first dialysate pump housed by the blood treatment machine, a second dialysate pump housed by the blood treatment machine; and a fluid cassette including an upper portion and a lower portion. The fluid cassette further includes a blood pumping tube extending from the upper portion to the lower portion of the fluid cassette, a first dialysate pumping tube extending from the upper portion to the lower portion of the fluid cassette, and a second dialysate pumping tube extending from the upper portion to the lower portion of the fluid cassette.

Dialysis system with enhanced features

A dialysis system includes a dialysis fluid cassette-based membrane blood pump; a dialyzer in fluid communication with the blood pump: first and second dialysis fluid cassette-based balance chambers each having (i) a fresh dialysis fluid compartment in fluid communication with the dialyzer and (ii) a spent dialysis fluid compartment; a dialysis fluid cassette-based fresh dialysis fluid membrane pump in fluid communication with the fresh dialysis fluid compartments of the first and second balance chambers; a dialysis fluid cassette-based spent dialysis fluid membrane pump in fluid communication with the dialyzer and the spent dialysis fluid compartments of the first and second balance chambers; and arterial and venous lines in fluid communication with the dialyzer for patient connection, the arterial and venous lines each including a contact used for electrically detecting a patient access disconnection.

Methods and systems for treating eclampsia or pre-eclampsia

Disclosed are methods and apparatuses for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using ex vivo treatment with an anti-sFlt-1 receptor (sFlt-1) antibody bound to a solid support in order to reduce blood levels of sFlt-1. Further disclosed are the sequences of the heavy chain and light chain CDRs of the anti-sFlt-1 antibodies.

AIRTRAP, SYSTEM AND METHOD FOR REMOVING MICROBUBBLES FROM A FLUID STREAM

An airtrap for a medical or physiological fluid in one embodiment includes a conical housing having a radius that increases from its top to its bottom when the housing is positioned for operation; a medical or physiological fluid inlet located at an upper portion of the conical housing; a medical or physiological fluid outlet located at a lower portion of the conical housing, the inlet and the outlet positioned and arranged so that medical or physiological fluid spirals in an increasing arc around an inside of the conical housing downwardly from the inlet to the outlet; and a gas collection area located at an upper portion of the conical housing. In another embodiment, the airtrap is shaped like a seahorse having a head section and a tail section. Any of the airtraps herein may be used for example in blood sets, peritoneal dialysis cassette tubing, and drug delivery sets.

Ozone-therapy blood treatment

A machine for ozone-therapy blood treatment having an extracorporeal circuit (1) comprising a filter (9), designed to produce a plasma component from the blood of a patient (P), an arterial line (3), designed for transport of the blood from the patient (P) to the filter (9), a venous line (4), designed for transport of the blood from the filter (9) to the patient (P), a reaction chamber (11), in which the plasma component is made to react with a gas containing ozone, a delivery line (12), designed for transport of the plasma component from the filter (9) to the reaction chamber (11), a return line (13), designed for transport of the plasma component that has reacted with the ozone from the reaction chamber (11) to the venous line (4), and an assembly for preparation and movement of the ozone (14), designed for the production of the ozone and its inlet into the reaction chamber (11).

EXTRACORPOREAL BLOOD CLEANING

System for obtaining immunoglobulin from blood

PROCESS AND SYSTEM FOR ACELLULAR THERAPY

EXTRACORPOREAL DEVICE AND MATRIX FOR REMOVING AMMONIA FROM BIOLOGICAL FLUIDS, METHODS AND USES THEREOF

СЕПАРАЦИОННЫЙ МАТЕРИАЛ, ВКЛЮЧАЮЩИЙ ПРОИЗВОДНЫЕ ФОСФОРИЛХОЛИНА

Изобретение относится к соединению формулы (), сепарационному материалу формулы (II), колонке для экстракорпорального удаления С-реактивного белка (СРБ) и устройству ее содержащему, которые могут быть применены в медицине:(II)где b выбран из 2 и 3; X выбран из -SH, -NH, -C≡CH, -CH=CH, -Nи -CHO; Rи Rвыбраны из -CH, -CH, -CH, -CH, -CHи -CH, или Rи Rобразуют вместе с атомом азота, с которым они соединены, гетероцикл, выбираемый из:,игде атомы водорода могут быть заменены атомами фтора; -L- в формуле (I) выбран из-(CH)-O-C(O)-NH-(CH)-, -(CH)-O-(CH)-, -(CH)-C(O)-NH-(CH)-, -(CH)-NH-C(O)-(CH)-, -(CH)-C(O)-NH-(CH)-O-(CH)-, -(CH)-O-C(O)-NH-(CH)-O-(CH)-, -(CH)-C(O)-NH-(CH)-C(O)-NH-(CH)-O-(CH)-, и -(CH)-O-C(O)-NH-(CH)-C(O)-NH-(CH)-O-(CH)-; m, n, p1, p2, o, r, q выбраны из 1, 2, 3, 4, 5, 6, 7, 8, 9, 10; Y выбран из -CH(OH)-CH-NH-, -CH(OH)-CH-S-, -CH-NH-, -NH-CH-, -CH-CH-S-, -S-CH-CH-,,,,,,,и;-L- в формуле (II) выбран из -L-, -L-L-, -L-L-L- и -L-L-L-L-L-, где -L- выбран из -(CH)-, -(CH-CH-O)-CH-; -L ...

СПОСОБ ЭКСТРАКОРПОРАЛЬНОЙ МОДИФИКАЦИИ ПЛАЗМЫ КРОВИ ПЕРЕД ЕЕ РЕИНФУЗИЕЙ

Способ экстракорпоральной модификации плазмы крови может быть использован для лечения заболеваний, связанных с активацией коагуляционного потенциала плазмы и повышением функциональной активности тромбоцитов. Полученную методом плазмафереза плазму крови перед ее сорбционной обработкой нагревают при 56oС в течение 25-30 мин с последующим центрифугированием при 3500 об/мин в течение 30 мин с удалением осадка. 1 ил., 4 табл.

СПОСОБ ОЧИСТКИ КРОВИ ПРИ ЛЕЧЕНИИ БОЛЬНЫХ, СТРАДАЮЩИХ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ И УСТРОЙСТВО ДЛЯ ЕГО ОСУЩЕСТВЛЕНИЯ

Изобретение относится к медицине и может быть использовано для лечения больных, страдающих почечной недостаточностью. Согласно изобретению кровь последовательно пропускают через гемофильтрационный элемент и гемодиализный элемент, а ультрафильтрат - через выпускной соединитель гемофильтрационного элемента и фильтр, такой как фильтр из активированного угля, предпочтительно с активированным углем не покрытым оболочкой, вводится в виде регенерированного ультрафильтрата в канал. Таким образом, очищенный ультрафильтрат используют в качестве реинфузионного раствора для повторного введения больному. 2 с. и 11 з.п. ф-лы, 1 табл., 5 ил.

УПРОЩЕННАЯ РЕГЕНЕРАЦИЯ АФЕРЕЗНЫХ КОЛОНОК

Группа изобретений относится к медицинской технике. Устройство для афереза для экстракорпорального удаления C-реактивного белка (CRP) из крови содержит систему экстракорпорального кровообращения для крови, средство для формирования и регулирования потока крови в системе экстракорпорального кровообращения, сепаратор клеток для разделения крови на плазму крови и клеточные компоненты, аферезную колонку для удаления CRP методом аффинной хроматографии из крови. Система экстракорпорального кровообращения содержит артериальную магистраль до сепаратора клеток, магистраль плазмы от сепаратора клеток до аферезной колонки, магистраль плазмы для CRP-обедненной плазмы крови из аферезной колонки до точки P1, магистраль клеточной массы для отделенных клеточных компонентов от сепаратора клеток до точки P1 и венозную магистраль, исходящую из точки P1. Центральный процессор служит для управления устройством для афереза. Соединительная магистраль служит для подсоединения контейнера для жидкостей к артериальной ...

СПОСОБ ИММУНОКОРРЕКЦИИ НОСИТЕЛЯ ПАТОГЕНА

Использование: в области медицины. Сущность изобретения: при экстракорпоральной очистке крови носителя патогена ему предварительно вводят лимфостимуляторы и дифференцируют кровь на фракцию эритроцитов и плазмы. Эритроциты отмывают, а на плазму воздействуют иммобилизованными белками: клеточными рецепторами носителя, комплементарными к патогену, протеином А, β- и i-цепями белка гистосовместимости класса II и активационными антигенами. В работу берут активационные антигены, β- и i-цепи белка гистосовместимости класса II того органа, который поражен у носителя. При использовании донорского материала в работу берут активационные антигены, β- и i-цепи белков, которые структурно идентичны или сходны с белками того штамма патогена, которым инфицирован носитель, отмытые эритроциты и обработанную плазму объединяют и вводят больному. Технический результат: эффективная очистка крови носителя патогена от широкого спектра биологически активных токсических веществ эндо- и экзогенной природы. 8 з.п.ф-лы ...

СЕПАРАЦИОННЫЙ МАТЕРИАЛ, ВКЛЮЧАЮЩИЙ ПРОИЗВОДНЫЕ ФОСФОРИЛХОЛИНА

KREBSBEHANDLUNG DURCH ULTRAPHERESE UNTER ENTFERNUNG VON VERBINDUNGEN UNTER 120,000 DALTONS

Apparat zur extrakorporalen Blutbehandlung

Method and apparatus for the selective extracorporeal precipitation of low density lipoproteins from whole serum or plasma

A method for the selective extracorporeal precipitation of low density lipoproteins or beta -lipoproteins from whole serum or plasma is characterised in that heparin in a buffer is added to the whole serum or plasma, and the beta -lipoprotein-heparin complex which is formed is precipitated at the isoelectric point at a pH of 5.05 to 5.25 and then removed, or the precipitate or filtrate is analysed further for diagnostic purposes. An apparatus for the extracorporeal precipitation of blood constituents having a container to which blood or blood constituents from a patient are fed via a first pump, and having a filter which is downstream of the container and whose filter outlet is connected to a line leading back to the patient, is characterised in that the filter has a second outlet for the precipitate, which outlet is connected to a return line leading into the container, in that the container is connected via a second pump to the outlet of a first vessel containing a treating agent, and ...

Haemodialysis appts. having two dialyser units - 1st is in extracorporeal circuit and 2nd is to regenerate waste dialysate to return to 1st dialyser.

Haemodialysis equipment includes a first haemodialyser (3) in an extracorporeal circuit of the patient being treated and a second dialyser (sepn dialyser) connected to the dialysate part of the first dialyser for regenerating the waste matter-rich dialysate which is then returned to the first dialyser. A pump (9) is used to transfer the waste matter-rich dialysate and is a second blood pump used for single needle dialysis. ADVANTAGE - The equipment of this patent of addn is more economic than that of the parent patent (DE4102693) which includes an expensive haemofilter.

Verwendung eines Hämodialysegerätes für eine Hämofiltrationsbehandlung

VERFAHREN UND VORRICHTUNG ZUR BEHANDLUNG VON ALLERGISCHEN KRANKHEITEN

METHODE ZUR BEHANDLUNG UND PRÄVENTION VON ANSTECKENDEN KRANKHEITEN

Blood filter

The present invention relates to a device for removal of haemolysis-derived components from blood, the device comprising a support and a plurality of binding agents bound to said support, wherein the binding agents comprise at least one iron-chelating molecule, at least one haem-binding molecule and at least one haemoglobin-binding molecule. Preferably the iron-chelating molecule is desferrioxamine, the haem-binding molecule is human serum albumin, and the haemoglobin-binding molecule is haptoglobin. Also claimed is a method of treating or preventing haemolysis-associated pathology in a subject by applying blood from a subject to the device and administering the treated blood to a subject.

Device and method for diabetes and other disorders

Blood plasma treating method and apparatus

Treating blood by separating plasma from other blood components, adding a precipitating agent for precipitating plasma components to the plasma to form a precipitate, removing the precipitate from the plasma, removing the precipitating agent from the plasma, and mixing the other blood components with the treated plasma.

EQUIPMENT FOR TREATING TUMORS OF MEANS OF SELECTIVE ONES PROTEIN DECREASE

DISTANCE OF PRIONEN FROM BLOOD, PLASMA AND OTHER LIQUIDS

TREATMENT F�R KARDIOVASKUL�RE AND ASSOCIATED DISEASES

GER�T F�R THE PLASMA CLEANING IN COMBINATION WITH PLASMA ADSORPTION PERFUSION BY USE OF A TRIKOMPARTIMENT DIALYSATORS

NANO- CLAY SORBENTIEN F�R DIALYSEGER�T

DEVICE FOR THE DISTANCE OF PROTEIN-BOUND SUBSTANCES

ARRANGEMENT FOR REMOVING OF ONE OR MORE PARLIAMENTARY GROUPS FROM TOTAL BLOOD, PLASMA OR OTHER AEHNLICHEN BODY FLUIDS.

DEVICE FOR THE DISTANCE OF HEAVY METAL IONS FROM BLOOD.

PROCEDURES FOR THE SELECTIVE ELIMINATION OF INORGANIC PHOSPHATE FROM LIQUIDS OF MEANS WITH POLYNUKLEAREN METALLIC OXIDE HYDROXIDES MODIFIED ADSORPTION MATERIALS

A method of treating and preventing infectious diseases

Patient-specific immunoadsorbents for extracorporal apheresis and methods of producing said immuno-adsorbers

Modular Extracorporeal Systems and Methods for Treating Blood-Borne Diseases

Extracorporeal systems and methods for treating blood-borne diseases in a subject or for developing drugs to treat blood-borne diseases include various environmental and treatment modules that can be tailored to a specific disease or infection. In certain embodiments of the systems and methods, a blood sample is treated with hydrostatic pressure, a pulsed electrical field, a pharmaceutical agent, microwave, centrifugation, sonification, radiation, or a combination thereof, under environmental conditions that are effective for the treatment.

Method and product for blood treatment and purification

Extracorporeal blood treatment is performed daily on a large number of patients by use of for example a dialysis filter, plasma filter or a centrifuge. The purpose of the treatment is to separate minor components and molecules in a liquid or in the blood from larger ones, for example in connection with different disease conditions or with a view to extracting blood plasma, target substances such as blood components or molecules from for example blood donors. According to the present invention two separation steps are used together with a solution or a suspension containing at least one component, which specifically may bind to the component or the blood component to be specifically reduced, or to be refined/extracted during the treatment or during the blood treatment.

Method and system to remove soluble tnfr1, tnfr2 and il2 in patients

A method, and system, to induce remission in diseases characterized by excess production of sTNR and interleukin 2 has been developed. In the most preferred embodiment, the system consists of antibodies to sTNFR1, sTNFR2 and sIL2R immobilized in a column containing a material such as SEPHAROSE™. The patient is connected to a pheresis machine which separates the blood into the plasma and red cells, and the plasma is circulated through the column until the desired reduction in levels of sTNFR1, sTNFR2, and IL2 is achieved, preferably to less than normal levels. In the preferred method, patients are treated three times a week for four weeks. This process can be repeated after a period of time. Clinical studies showed reduction in tumor burden in patients having failed conventional chemotherapy and radiation treatments.

Methods to detect and treat diseases

The current invention discloses methods to treat disease caused by virus infection, bacterial infection, parasites infection, autoimmune disease, disease caused by production of unwanted antibodies, sepsis as well as methods to treat cancer and methods for virus infection detection using blood purification method. The current invention provides a method to treat pathogen infection by inactivating the pathogens in the blood. During the treatment, blood is withdrawn from a patient and is separated into its plasma and cellular components. The plasma portion is treated with physical means such as UV radiation to inactivate the pathogens inside and then is returned to the patient. The current invention also provide a method to treat cancer especially to prevent tumor metastasis and tumor recurrence by removing and/or inactivating (e.g. killing) the circulating tumor cells (CTC) in the blood after removing the tumor or treating the tumor with therapeutical means.

Recirculating fluid filtration system

A fluid filtration system comprising a cross-flow filter is arranged to permit a first pump to recirculate part of the retentate of the filter to the inlet of the cross-flow filter and a second pump to return part of the permeate to the inlet of the cross-flow filter. A third pump is configured supply source fluid to the inlet of the filter. The flow path between the second pump and the cross-flow filter inlet may include an adsorption filter that may selectively remove contaminants, toxins, or pathogens in the permeate. A controller may control the first, second and third pumps to provide predetermined flow ratios among the fluid flow paths of the system in order to achieve a desired filtration level. This system may be applicable to the removal of harmful substances from blood, by first separating the plasma from the blood and then removing harmful substances from the plasma.

Closed-circuit device and methods for isolation, modification, and re-administration of specific constituents from a biological fluid source

The present invention relates to a method and apparatus for the isolation, modification and re-administration of a molecule or biomolecule, or a class of biomolecules, from the body fluid of a mammal via an extracorporeal closed circuit device. The device is able to capture and modify the biomolecule by the covalent or non-covalent attachment of a secondary molecule or protein, by cross-linking the captured molecule, or by altering the structure of the molecule (for example, by deglycosylation, peptide cleavage, or aggregation). The apparatus can be used to return the modified molecule or biomolecule to the mammalian subject. The device and methods may be utilized for the patient-specific diagnosis and/or treatment of a disease state which presents an associated molecule or protein in plasma or any other fluidized physiological system. The methods and apparatus may also be employed as a closed system allowing the on-line purification and/or modification of a target molecule or biomolecule from a fluid source such as a bioreactor or perfusion bioreactor.

Reduction of galectin-3 levels by plasmapheresis

The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.

EXTRACORPOREAL DEVICE AND MATRIX FOR REMOVING FIBRINOLYTIC PROTEINS FROM BIOLOGICAL FLUIDS, METHODS AND USES THEREOF

The presently disclosed subject-matter provides specific compositions, conjugates, device, kits and systems for depleting fibrinolytic agents from biological fluids. The presently disclosed subject-matter further relates to the resulting biological fluid products that are devoid in fibrinolytic activity, therapeutic methods and uses thereof. The conjugates comprise a particle, at least one linker and at least one amino acid, derivative thereof or analog thereof being at least one of 4-(aminomethyl)-cyclo-hexane-carboxylic acid (tranexamic acid), epsilon-amino caproic acid, lysine, cyclohexanecarboxylic acid and 4-methyl-cyclohexanecarboxylic acid. A plurality of different conjugates (e.g. differing in particle size or type of linker) can be used. 156-. (canceled)57. A plurality of conjugates or any composition comprising said plurality of conjugates , wherein each conjugate comprises a particle , at least one linker and at least one amino acid , derivative thereof or analog thereof , wherein the plurality of conjugates comprises at least two different conjugates , and wherein said amino acid , derivative thereof or analog thereof is at least one of 4-(aminomethyl)-cyclo-hexane-carboxylic acid (tranexamic acid) , ϵ-amino caproic acid lysine , cyclohexanecarboxylic acid and 4-methyl-cyclohexanecarboxylic acid.58. The plurality of conjugates or composition according to claim 57 , wherein the particles and/or the linkers of the at least two different conjugates are different claim 57 , and optionally wherein at least one of:(a) the particles have an average particle size of between about 90 μm to about 150 μm;(b) the linker comprises a linear chain of 1 atom to 40 atoms;(c) the ratio between the particle and the linker coverage of the particle's surface is about 9 to 23 μmol beads/ml drained medium;(d) the linker comprises at least one atom having a lone electron pair;(e) the particle is at least one of polysaccharide bead, glass beads, cotton bead, plastic bead, nylon ...

Method and device for treating cancer

A method and device treats cancer where blood from a cancer patient passes through an array of passageways within an interior of a chamber. The passageways include wells having porous membrane wall portions that enable a molecular-sized activating agent in a carrier fluid that enhances an immune response to pass through these porous wall portions. Pore size is such to allow the molecular-sized activating agent in the interior of the chamber to enter the wells yet prevents immune cells and cancer cells in the wells to pass through the porous wall portions into the interior of the chamber. Blood is retained in the wells so that it remains in contact with the immune cells and cancer cells for a predetermined period sufficient to enhance an immune response. Then the cells with an enhanced immune response are return to the patient.

Process for removing mercury ions from bodily fluids using titanium metallate ion exchange compositions

A process for removing Hg 2+ toxins from bodily fluids is disclosed. The process involves contacting the bodily fluid with a titanium metallate ion exchanger to remove the metal toxins in the bodily fluid, including blood and gastrointestinal fluid. Alternatively, blood can be contacted with a dialysis solution which is then contacted with the ion exchanger. The titanium metallate ion exchangers are represented by the following empirical formula: A m TiNb a Si x O y . A composition is provided with the combination of the titanium metallate ion exchanger and bodily fluids or dialysis solutions. Also, provided is an apparatus comprising a matrix and the titanium metallate ion exchanger.

METHOD FOR EX VIVO TREATING BLOOD OR PLASMA

A method for ex vivo treating blood or plasma is provided. The method includes (a) ex vivo contacting a blood or plasma with an enzyme composition to react the enzyme composition with the blood or plasma, wherein the enzyme composition is capable of eliminating electronegative low-density lipoprotein from the blood or plasma by the activity of the enzyme composition, and the enzyme composition is selected from a group consisting of: a first enzyme for eliminating a glycan residue of an electronegative low-density lipoprotein (LDL); a second enzyme for eliminating ceramide carried by a electronegative low-density lipoprotein (LDL); and a combination thereof; and (b) terminating contact between the blood or plasma and the enzyme composition to terminate the reaction of the enzyme composition with the blood or plasma. 1. A method for ex vivo treating blood or plasma , comprising: a first enzyme for eliminating a glycan residue of an electronegative low-density lipoprotein (LDL);', 'a second enzyme for eliminating ceramide carried by a electronegative low-density lipoprotein (LDL); and', 'a combination thereof; and, '(a) ex vivo contacting a blood or plasma with an enzyme composition to react the enzyme composition with the blood or plasma, wherein the enzyme composition is capable of eliminating electronegative low-density lipoprotein from the blood or plasma by the activity of the enzyme composition, and the enzyme composition is selected from a group consisting of(b) terminating contact between the blood or plasma and the enzyme composition to terminate the reaction of the enzyme composition with the blood or plasma.2. The method for ex vivo treating blood or plasma as claimed in claim 1 , wherein the step (a) is performed for about 0.25-8 hours.3. The method for ex vivo treating blood or plasma as claimed in claim 1 , wherein the step (a) is performed at about 4-40° C.4. The method for ex vivo treating blood or plasma as claimed in claim 1 , wherein the step (a) is ...

BLOOD FILTER

A blood filter device having an iron-chelating molecule, a haem-binding molecule and a haemoglobin-binding molecule bound to a support. Use of the device in a vessel containing blood, for example a blood bag or a flow line, removes haemolysis-derived components from the blood. 1. A device for removal of haemolysis-derived components from blood , the device comprising:a support,a plurality of binding agents bound to said supportwherein the binding agents comprise at least one iron-chelating molecule, at least one haemoglobin-binding molecule, and at least one haem-binding molecule.2. A device according to further comprising a vessel for the storage or passage of blood claim 1 , wherein the vessel contains the support.3. A device according to claim 1 , wherein the support is a plurality of beads.4. A device according to claim 1 , wherein each bead of the plurality of beads is bound to no more than one of: the iron-chelating molecule claim 1 , the haemoglobin-binding molecule claim 1 , and the haem-binding molecule.5. A device according to claim 1 , wherein the support is a single element to which at least one iron-chelating molecule claim 1 , at least one haemoglobin-binding molecule claim 1 , and at least one haem-binding molecule are bound claim 1 , preferably wherein all of the plurality of binding agents are bound to the single element.6. A device according to claim 1 , wherein the support is wholly or partially integrated with the vessel.7. A device according to wherein the support is not integrated with the vessel.8. A device according to claim 1 , wherein the support comprises an insoluble polymer or a glass claim 1 , or preferably wherein the insoluble polymer is a natural functionalised biopolymer claim 1 , preferably a polysaccharide polymer claim 1 , preferably agarose claim 1 , or further preferably wherein the insoluble polymer is a synthetic polymer claim 1 , preferably a synthetic co-polymer claim 1 , preferably a PEGylated synthetic polymer.910.-. ( ...

PURIFICATION OF BLOOD SAMPLES WITH HEMOLYSIS

The present invention relates to removal of hemoglobin from a sample. In particular the present invention relates to a method in which a protein with specificity towards hemoglobin and/or the complex of hemoglobin with haptoglobin is immobilized on a solid support and utilized to remove hemoglobin from a sample comprising hemoglobin, such as a hemolysed sample obtained from a subject. 220-. (canceled)21. The method according to claim 1 , wherein the binding moiety comprises at least one near iron transporter (NEAT) domain.22. The method according to claim 21 , wherein the at least one NEAT domain comprises a sequence selected from:i. SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and combinations thereof, orii. a NEAT domain having at least 75% sequence identity to the full-length sequences of any one of SEQ ID NOs:1-6 and combinations thereof.23. The method according to claim 21 , wherein the NEAT domain comprises a sequence selected from:i. SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and combinations thereof, orii. a NEAT domain having at least 75% sequence identity to the full-length sequence of any one of SEQ ID NOs:1-3 and combinations thereof.24. The method according to claim 1 , wherein the at least one non-mammalian protein or protein fragment comprises a coupling moiety.25. The method according to claim 24 , wherein the coupling moiety is selected from a cysteine residue claim 24 , an unnatural amino acid claim 24 , an amino acid linker claim 24 , an amino group claim 24 , a consensus sequence or polyethylene glycol (PEG).26. The method according to claim 24 , wherein the coupling moiety is a cysteine residue recombinantly introduced into the at least one non-mammalian protein or protein fragment.27. The method according to claim 24 , wherein the at least one non-mammalian protein or protein fragment is immobilized on the solid support via the coupling moiety.28. The method according to claim 1 , wherein the sample is selected from ...

DIALYSIS SYSTEM HAVING INDUCTIVE HEATING

A dialysis fluid system includes a dialysis fluid inlet; a dialysis fluid outlet; a pump positioned and arranged to pump dialysis fluid through the dialysis fluid inlet and the dialysis fluid outlet; and an inductive heater located between the dialysis fluid inlet and the dialysis fluid outlet, the inductive heater including a fluid flowpath positioned and arranged to receive non-heated dialysis fluid from the dialysis fluid inlet and to output heated dialysis fluid to the a dialysis fluid outlet, a conductive heater element located within the fluid flowpath so as to be or act as a secondary coil of a transformer, and a primary coil of the transformer located outside of the fluid flowpath and positioned so as to magnetically induce a current into the conductive heater element, causing the conductive heater element and surrounding fluid to heat. 1. A dialysis fluid system comprising:a dialysis fluid inlet;a dialysis fluid outlet;a pump positioned and arranged to pump dialysis fluid through the dialysis fluid inlet and the dialysis fluid outlet; and a fluid flowpath positioned and arranged to receive non-heated dialysis fluid from the dialysis fluid inlet and to output heated dialysis fluid to the dialysis fluid outlet,', 'a conductive heater element located within the fluid flowpath so as to be or act as a secondary coil of a transformer, and', 'a primary coil of the transformer located outside of the fluid flowpath and positioned so as to magnetically induce a current into the conductive heater element, causing the conductive heater element and surrounding dialysis fluid to heat., 'an inductive heater located between the dialysis fluid inlet and the dialysis fluid outlet, the inductive heater including'}2. The dialysis fluid system of claim 1 , wherein the fluid flowpath and the conductive heater element are located within a heater housing in fluid communication with the dialysis fluid inlet and the dialysis fluid outlet.3. The dialysis fluid system of claim 2 , ...

STOCK SOLUTION CONCENTRATING DEVICE, STOCK SOLUTION TREATMENT DEVICE, AND CIRCULATION-TYPE TREATMENT DEVICE

Provided are a stock solution concentrating device, a stock solution treatment device and a circulation-type treatment device that can prevent the deposition of cells and the like on a filtration member and that can continuously filter and concentrate a stock solution such as pleural and ascitic fluid or blood plasma. The stock solution concentrating device concentrates a stock solution such as pleural and ascitic fluid or blood plasma to form a concentrated solution, and is equipped with: a filter () having a filtration member that filters the stock solution; a concentrator () to which the filtrate which has been filtered is supplied, and which concentrates the filtrate to form a concentrated solution; and a stock solution supply unit that supplies the stock solution to the filter (). The stock solution supply unit has a supply amount adjustment function for adjusting the amount of the stock solution supplied to the filter. 121-. (canceled)22. A stock solution concentrating device for concentrating a stock solution such as pleural and ascitic fluid or blood plasma to form a concentrated solution , the device comprising:a filter having a filtration member that filters the stock solution;a concentrator to which a filtrate which has been filtered by the filter is supplied, and which concentrates the filtrate to form the concentrated solution; anda stock solution supply unit that supplies the stock solution to the filter,wherein the stock solution supply unit has a supply amount adjustment function for adjusting the amount of the stock solution supplied to the filter,the filter includesa supply port to which the stock solution is supplied, anda separate liquid discharge port from which a separate liquid which has been separated from the filtrate is discharged,the stock solution supply unit includesa flow path that supplies the stock solution to the supply port of the filter, anda circulation flow path that supplies the separate liquid discharged from the separate ...

UREA SEQUESTRATION COMPOSITIONS AND METHODS

Graphene-based materials for sequestering urea from aqueous solutions are provided. The graphene-based materials include graphene aggregates as well as graphene oxides. 1. A method comprising:contacting a fluid comprising urea with a mass of graphene-based material particles;sorbing at least a portion of the urea into or onto the graphene-based material particles to produce a graphene-based material/urea complex; andreducing the level of urea in the fluid wherein the amount of urea in the graphene-based material/urea complex is greater than 25 mg urea per gram of graphene-based material.2. The method of wherein the fluid is selected from at least one of an aqueous fluid claim 1 , water claim 1 , whole blood claim 1 , blood plasma claim 1 , processed blood claim 1 , preserved blood claim 1 , serum claim 1 , plasma claim 1 , clotted blood claim 1 , anti-clotted blood claim 1 , centrifuged blood claim 1 , hematocrit claim 1 , biological filtrate claim 1 , ultrafiltrate claim 1 , dialysate claim 1 , extracellular fluids claim 1 , intracellular fluids claim 1 , interstitial fluids claim 1 , lymphatic fluids claim 1 , transcellular fluids claim 1 , urine claim 1 , urine-derived fluids claim 1 , agricultural runoff and sewage.3. (canceled)4. The method of wherein the concentration of urea in the fluid is reduced by greater than 10 percent by weight.5. The method of comprising agitating claim 1 , stirring claim 1 , shaking claim 1 , sonicating claim 1 , flowing claim 1 , cooling and/or heating a suspension of the graphene-based material particles in the fluid.6. The method of claim 1 , the method comprising flowing the fluid through a bed comprising graphene-based material particles.7. The method of wherein the graphene-based material is graphene oxide having an atomic ratio of carbon to oxygen of from 20:1 to 1.5:1.8. The method of wherein the graphene-based material is a graphene aggregate.9. The method of comprising removing at least one non-urea component of the fluid ...

Biocompatible nanomagnetic discs and methods of use thereof

Provided herein are compositions including biocompatible magnetizeable nanoparticles. The nanoparticles have a diameter (average diameter) from about 10 to about 300 nanometers and are biocompatible and magnetic. The nanoparticles may be a disc formed from iron oxide. The disc may be conjugated to a target-binding moiety capable of binding a target. The target may be cancer cells, pathogens, fat cells, or atherosclerotic plaques.

Dialysis system including automatic priming

A hemodialysis system comprising: a source of priming fluid; an extracorporeal circuit including an arterial line, a venous line, and a drip chamber; a level sensor operable with the drip chamber; a reversible blood pump operable with the extracorporeal circuit; a connection between the arterial and the venous line; and a priming sequence in which priming fluid from the source is pumped in a reverse pump direction through the extracorporeal circuit and reversibly in a normal pump direction through the extracorporeal circuit, wherein an output from the level sensor is used to determine when to stop pumping in at least one of the directions.

CLEANING OF BIOLOGICAL FLUID

The present invention relates to removal of protein bound deleterious substances from an extracorporeal biological fluid by changing the affinity of the substance to the protein. The invention relates to the use of displacer substances for removal of deleterious substances. The present invention also relate to a method of removal, a system, a cleaning fluid comprising the displacer substances for removal of deleterious substances. 1. Use of a substance selected from C-C-fatty acid , or derivatives thereof , or salts thereof; and salicylic acid , derivatives thereof , or salts thereof; or combinations thereof , as displacer substance for removing a deleterious substance bound to a protein in an extracorporeal biological fluid.2. Use according to claim 1 , wherein the displacer substance is a C-C-fatty acid claim 1 , or derivatives thereof claim 1 , or salts thereof3. Use according to claim 1 , wherein the displacer substance is salicylic acid claim 1 , derivatives thereof claim 1 , or salts thereof.4. Use according to any of to wherein the deleterious substance comprises p-cresol claim 1 , p-cresyl sulfate claim 1 , indoxyl sulfate claim 1 , CMPF claim 1 , and combinations thereof.5. Use according to claim 1 , wherein the protein is albumin.6. Use according to claim 1 , wherein the extracorporeal biological fluid is selected from blood; blood plasma; or peritoneal fluid.7. Use according to claim 1 , wherein the displacer substance is a combination of C-C-fatty acids claim 1 , or derivatives thereof claim 1 , or salts thereof claim 1 , and salicylic acid claim 1 , derivatives thereof; preferably the displacer substance is a combination of sodium octanoate (C-fatty acid salt) with one or both of sodium salicylate and sodium acetylsalicylate.8. Use of a displacer substance selected from C-C-fatty acid claim 1 , or derivatives thereof claim 1 , or salts thereof claim 1 , salicylic acid claim 1 , or derivatives thereof claim 1 , or salts thereof; or combinations thereof ...

Extracorpereal fluidic device for collecting circulating tumor cells and method of use thereof

A device can be used to retain circulating tumor cells (CTCs). The device can include a cross-flow module with a retentate channel and a permeate channel. A filter in the cross-flow module can separate the retentate channel from the permeate channel. The filter can be constructed such that CTCs are retained in the retentate channel while other cells can pass through the filter into the permeate channel. A recirculation channel can direct a flow from an outlet of the retentate channel back to an inlet of the retentate channel to thereby concentrate CTCs in the retentate flow.

POROUS CARBON STRUCTURE PRODUCTION

A process is provided for producing a structure into which blood or other bio-fluids can flow by capillary action, e.g. for a whole blood microsampling probe. The process comprises mixing particles of novolak resin and particles of hydrocarbon polymer, producing an uncarbonized structure from the mixture by pressurised moulding and carbonizing the moulded structure, the hydrocarbon resin being a polymer such as polystyrene that on pyrolysis has a zero carbon yield, and the particles of the hydrocarbon polymer leaving voids in the carbonized structure of sufficient size for flow of whole blood into and through the structure. The particles may be of partly cured and milled novolak resin, the novolak particles when in the moulded structure not exhibiting bulk flow during carbonization but sintering at inter-particle contact points during carbonization to provide a consolidated structure. In this variant, ethylene glycol may be used as a sintering aid. Alternatively, the particles may be of fully cured and milled novolak resin, and are mixed with the hydrocarbon polymer , the lubricant and with a binder such as lignin for providing a consolidated structure. 1. A process for producing a structure into which blood or other bio-fluids can flow by capillary action , said process comprising:mixing particles of novolak resin and particles of hydrocarbon polymer;producing an uncarbonized structure from the mixture by pressurised moulding; andcarbonizing the moulded structure, the hydrocarbon polymer being a polymer that on pyrolysis has a zero carbon yield, and the particles of the hydrocarbon polymer leaving voids in the carbonized structure of sufficient size for flow of whole blood into and through the structure to be enhanced.2. The process of claim 1 , wherein the particles of novolak resin are of mean size 40-70 μm and have been classified to remove powder of size less than 20 μm.3. The process of claim 1 , wherein the particles of hydrocarbon polymer have a mean ...

APPARATUS FOR CARRYING OUT AN APHERESIS TREATMENT

The present invention relates to an apparatus for carrying out an apheresis treatment, wherein the apparatus has an extracorporeal circuit in which a regenerable single adsorber is located for separating substances from blood or for separating substances from plasma acquired by means of a plasma separator, wherein a line is provided for conducting the blood or the plasma which extends to the adsorber and via which blood or plasma is applied to the adsorber, wherein a reservoir is provided for receiving blood or plasma and is arranged upstream of the adsorber in the line or is in communication with the line upstream of the adsorber; and in that a controller or switching means is provided which is configured such that the reservoir is filled with blood or plasma and the application of blood or plasma to the adsorber is suppressed when the regeneration of the adsorber is carried out. 1. An apparatus for carrying out an apheresis treatment , wherein the apparatus has an extracorporeal circuit in which a regenerable single adsorber is located for separating substances from blood or for separating substances from plasma acquired by means of a plasma separator , wherein a line is provided for conducting the blood or the plasma which extends to the adsorber and via which blood or plasma is applied to the adsorber , characterized in that a reservoir is provided for receiving blood or plasma and is arranged upstream of the adsorber in the line or is in communication with the line upstream of the adsorber; and in that a controller or switching means is provided which is configured such that the reservoir is filled with blood or plasma and the application of blood or plasma to the adsorber is suppressed when the regeneration of the adsorber is carried out.2. An apparatus in accordance with claim 1 , characterized in that a first extracorporeal circuit is provided in which the plasma separator is located whose secondary side is adjoined by a second extracorporeal circuit claim 1 ...

BIOCHEMISTRY REACTIVE MATERIAL AND DEVICE FOR ELIMINATING ELECTRONEGATIVE LOW-DENSITY LIPOPROTEIN (LDL) AND METHOD FOR TREATING BLOOD OR PLASMA EX VIVO TO ELIMINATE ELECTRONEGATIVE LOW-DENSITY LIPOPROTEIN THEREIN

The present disclosure provides a biochemistry reactive material, including a substrate and an enzyme composition immobilized on the substrate. The enzyme composition is selected from a group consisting of a first enzyme, a second enzyme, and a combination thereof. The first enzyme is used for eliminating a glycan residue of an electronegative low-density lipoprotein (electronegative LDL). The second enzyme is used for eliminating ceramide carried by an electronegative low-density lipoprotein. The biochemistry reactive material is capable of eliminating electronegative low-density lipoprotein. 1. A biochemistry reactive material , comprising:a substrate; and a first enzyme for eliminating a glycan residue of an electronegative low-density lipoprotein (electronegative LDL);', 'a second enzyme for eliminating ceramide carried by an electronegative low-density lipoprotein; and', 'a combination thereof,, 'an enzyme composition immobilized on the substrate, wherein the enzyme composition is selected from a group consisting ofwherein the biochemistry reactive material is capable of eliminating electronegative low-density lipoprotein.2. The biochemistry reactive material as claimed in claim 1 , wherein the substrate comprises silica gel claim 1 , cellulose claim 1 , diethylaminoethyl cellulose (DEAE cellulose) claim 1 , chitosan claim 1 , polystyrene claim 1 , polysulfone claim 1 , polyethersulfone claim 1 , acrylate resin or polysaccharide.3. The biochemistry reactive material as claimed in claim 1 , wherein the substrate has a particle structure or a hollow-tube structure.4. The biochemistry reactive material as claimed in claim 1 , wherein the substrate is a cellulose bead.5. The biochemistry reactive material as claimed in claim 1 , wherein the substrate is a chitosan bead.6. The biochemistry reactive material as claimed in claim 1 , wherein the substrate is a cellulose hollow fiber claim 1 , a polysulfone hollow fiber claim 1 , epoxy acrylic resin or a ...

Filter for purifying blood

A filter for purifying blood (1, 100), comprising a container body (2, 102) in which there are: —an intake port (3, 103) for an incoming blood stream (4, 104), —a first discharge port (5, 105) for an outgoing blood stream (6, 106), and —a second discharge port (7, 107) for a purified plasma stream (8, 108); the container body (2, 102) comprises first filtering means (9, 109) adapted to separate a stream of plasma to be purified (10, 100) from the incoming blood stream (4, 104), and second filtering means (11, 111) adapted to purify the stream of plasma to be purified (10, 110) to obtain the purified plasma stream (8, 108).

Blood Treatment With Inactivation Of Circulating Nucleic Acids

The present invention relates to a device for the treatment of blood comprising a solid phase on which a polypeptide is immobilized which is suitable for the inactivation of free nucleic acids. Suitable polypeptides are, for example, deoxyribonucleases, ribonucleases, DNA methyltransferases or cytosine deaminases. The invention further comprises the use of such devices for the treatment of patients suffering from chronic kidney failure, cancer or lupus erythematosus, as well as methods and systems for the treatment of blood, wherein free nucleic acids are inactivated outside the body. 1. A device for the treatment of blood , comprising(a) tubes for whole blood or blood plasma to flow through from and to the patient,(b) a solid phase on which a polypeptide is immobilized which is suitable for the inactivation of free nucleic acids.2. The device according to claim 1 , wherein the device furthermore comprises (c) a dialyzer or haemofilter.3. The device according to claim 1 , wherein the polypeptide is selected from the group consisting of deoxyribonucleases claim 1 , ribonucleases claim 1 , endonucleases claim 1 , exonucleases claim 1 , endoribonucleases claim 1 , exoribonucleases or peptides with nuclease activity.4. The device according to claim 1 , wherein the polypeptide is selected from the group consisting of DNA methyltransferases 1 (DNMT1) or peptides with methyltransferase activity.5. The device according to claim 1 , wherein the polypeptide has a cytosine deaminase activity.6. The device according to claim 2 , wherein the solid phase is upstream of the dialyzer or haemofilter.7. The device according to claim 2 , wherein the solid phase is located within the dialyzer or haemofilter.8. The device according to claim 1 , wherein the device furthermore comprises (d) a plasma filter.9. The device according to claim 1 , wherein the solid phase on which the polypeptide is immobilized comprises a hollow fibre membrane claim 1 , beads or a non-woven.10. The device ...

Recirculating dialysate fluid circuit for measurement of blood solute species

A blood based solute monitoring system for measuring at least one blood solute species that has a first recirculation flow path in communication with a dialyzer. The first recirculation flow path is configured to allow a fluid to recirculate through a dialyzer such that the concentration of at least one solute species in the fluid becomes equilibrated to the solute species concentration of the blood compartment of the dialyzer. The blood solute monitoring system has at least one sensor to measure a fluid characteristic.

Adsorbing material for multiple pathogenic factors of sepsis as well as preparation method and application thereof

An adsorbing material for multiple pathogenic factors of sepsis as well as a preparation method and an application thereof are provided. The adsorbing material is formed by coupling a carrier with good mechanical performance and blood compatibility and a ligand with the capacity to adsorb multiple pathogen-associated molecular patterns, and is capable of effectively adsorbing bacterial endotoxin, bacterial genomic DNA, peptidoglycan, lipoteichoic acid, virus RNA, and zymosan from fluids such as blood and the like, and in particular has application value in blood purification for treatment of sepsis.

THE USE OF A HEMOCOMPATIBLE POROUS POLYMER BEAD SORBENT FOR REMOVAL OF PAMPS AND DAMPS

The invention concerns biocompatible polymer systems comprising at least one polymer sorbent with a plurality of pores, said polymer designed to adsorb pathogen-associated molecular pattern molecules and damage-associated molecular pattern molecules. Also disclosed herein are methods for reducing contamination in a biological substance, or treating contamination in a subject, by one or more pathogen-associated molecular pattern molecules and damage-associated molecular pattern molecules, by contacting the biological substance with an effective amount of sorbent capable of sorbing the toxin. 1. A biocompatible polymer system comprising at least one polymer , said polymer system capable of adsorbing (i) pathogen-associated molecular pattern molecules (PAMPS) and (ii) damage-associated molecular pattern molecules (DAMPS) having a molecular weight of from less than about 0.5 kDa to about 1 ,000 kDa.2. The biocompatible polymer system of wherein the polymer comprises a plurality of pores and the polymer's pore structure has a total volume of pore sizes in the range of from 50 Å to 40 claim 1 ,000 Å greater than 0.5 cc/g and less than 5.0 cc/g dry polymer.3. The biocompatible polymer system of wherein the polymer is hemocompatible.4. The biocompatible polymer system of wherein the geometry of said polymer system is a spherical bead.5. The biocompatible polymer system of wherein the toxins comprise PAMPs and DAMPS comprised of one or more of flagellins claim 1 , lipopeptides claim 1 , formyl peptides claim 1 , mycotoxins claim 1 , exotoxins claim 1 , endotoxins claim 1 , lipoteichoic acid claim 1 , cytolysins claim 1 , superantigens claim 1 , proteases claim 1 , lipases claim 1 , amylases claim 1 , enzymes claim 1 , peptides including bradykinin claim 1 , activated complement claim 1 , soluble receptors claim 1 , soluble CD40 ligand claim 1 , bioactive lipids claim 1 , oxidized lipids claim 1 , cellular DNA claim 1 , mitochondrial DNA claim 1 , pathogen or host derived RNA ...

Dialysis systems including therapy prescription entries

A dialysis system includes a dialysis machine configured to control fluid loss or ultrafiltration (“UF”) volume over a treatment; a graphical user interface (“GUI”) that allows selection of a prescription entry for the treatment; and a processor operating with the GUI, the processor programmed to (i) receive a plurality of prescription entries via a local or wide area mode of data communication, each prescription entry including at least one prescribed parameter for operating the dialysis machine to control the fluid loss or UF volume, and (ii) enable an operator to choose between the prescription entries provided at the GUI, and select one of the prescription entries for the treatment.

Hemodialysis system including a disposable cassette

A dialysis system includes a dialyzer, a sorbent cartridge configured to clean used dialysate from the dialyzer, a dialysate pump actuator configured to pump dialysate to the dialyzer, and a conductivity sensor located adjacent to a temperature sensor. The dialysis system also includes a disposable cassette configured to carry dialysate pumped by the dialysate pump actuator. The disposable cassette includes a combined conductivity and temperature sensor fluid chamber separate from the conductivity sensor and the temperature sensor and located so as to operate with the conductivity sensor and the temperature sensor, respectively, when mounted for operation.

BLOOD PURIFYING FILTER AND BLOOD PURIFYING APPARATUS

Provided are a blood purifying filter and a blood purifying apparatus having the same. The blood purifying filter includes a plasma separation filter separating plasma from blood, a hemodialysis filter configured in parallel with the plasma separation filter to remove toxins and waste products from blood, a housing providing installation space for the plasma separation filter and the hemodialysis filter, and plasma inlet and outlet ports provided in the housing. The housing further includes a wall, a lower cap and an upper cap which are coupled to the plasma separation filter and the hemodialysis filter. 1. A blood purifying filter comprising:a plasma separation filter separating plasma from blood;a hemodialysis filter removing toxins and waste products from blood;a housing providing installation space for the plasma separation filter and the hemodialysis filter and defining a plasma flow section outside the plasma separation filter and the hemodialysis filter,a plasma inlet port provided in the housing to allow separated plasma to flow into the plasma flow section; anda plasma outlet port provided in the housing to allow plasma having passed the plasma flow section to be discharged out of the blood purifying filter.2. The blood purifying filter of claim 1 , wherein the housing comprises:a wall having a cylindrical shape;a lower cap coupled to the plasma separation filter and the hemodialysis filter at a lower side of the wall; andan upper cap coupled to the plasma separation filter and the hemodialysis filter at an upper side of the wall.3. The blood purifying filter of claim 2 , wherein:the lower cap comprises a lower-cap insertion groove coupled to the plasma separation filter or the hemodialysis filter and a lower-cap passage which penetrates the lower cap, wherein one end of the lower-cap passage is connected to the lower-cap insertion groove; andthe upper cap comprises an upper-cap insertion groove coupled to the plasma separation filter or the hemodialysis ...

NANOCLAY SORBENTS FOR DIALYSIS

Dialysis is enhanced by using nanoclay sorbents to better absorb body wastes in a flow-through system. The nanoclay sorbents, using montmorillonite, bentonite, and other clays, absorb significantly more ammonium, phosphate, and creatinine, and the like, than conventional sorbents. The montmorillonite, the bentonite, and the other clays may be used in wearable systems, in which a dialysis fluid is circulated through a filter with the nanoclay sorbents. Waste products are absorbed by the montmorillonite, the bentonite, and the other clays and the dialysis fluid is recycled to a patient's peritoneum. Using an ion-exchange capability of the montmorillonite, the bentonite, and the other clays, waste ions in the dialysis fluid are replaced with desirable ions, such as calcium, magnesium, and bicarbonate. The nanoclay sorbents are also useful for refreshing a dialysis fluid used in hemodialysis and thus reducing a quantity of the dialysis fluid needed for the hemodialysis. 1. A system for removing body wastes from a fluid , the system comprising:a closed fluid loop for circulating blood to and from a hemodialysis machine;at least one pump attached to the loop for circulating the blood into and out of the hemodialysis machine and through the fluid loop;a replaceable cartridge housing connected to the closed fluid loop, the housing having a first end including an inlet, and a second end including an outlet;a filter with nanoclay particles, the filter attached to the fluid loop for removing body wastes from the blood, wherein the nanoclay particles comprise a processed nanoclay having at least one dimension from 1 nm to 200 nm, and wherein the processed nanoclay particles have been chemically enhanced with an acid to increase an acidity such that urea uptake is increased; anda drain container connected to the closed fluid loop for removing an excess fluid.2. The system of claim 1 , wherein the processed nanoclay is selected from the group consisting of expanded clays claim 1 ...

EXTRACORPOREAL DEVICES FOR METHODS FOR TREATING DISEASES ASSOCIATED WITH ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES

The invention relates to a blood treatment device configured to remove anti-neutrophil cytoplasmic antibodies (ANCAs) from the blood or blood plasma of a person in need thereof in an extracorporeal blood circuit, wherein the device comprises a matrix, and wherein said matrix comprises a monomeric form of proteinase 3 (PR3). The invention further relates to an extra-corporeal blood circuit comprising a blood treatment device of the invention and to the blood treatment device for use as a medicament or to methods of treating a medical condition associated with ANCA. 115.-. (canceled)16. A blood treatment device configured to remove anti-neutrophil cytoplasmic antibodies (ANCAs) from the blood or blood plasma of a person in need thereof in an extracorporeal blood circuit , wherein the device comprises a matrix , and wherein said matrix comprises a monomeric form of proteinase 3 (PR3).17. The blood treatment device according to claim 16 , wherein the monomeric form of proteinase 3 (PR3) comprises at least one mutation at Ile221 and/or Trp222.18. The blood treatment device according to claim 16 , wherein the monomeric form of proteinase 3 (PR3) comprises at least mutations at Ile221 and Trp222.19. The blood treatment device according to claim 16 , wherein the monomeric form of proteinase 3 (PR3) comprises the Ile221Ala and/or Trp222Ala mutations.20. The blood treatment device according to claim 16 , wherein the monomeric form of proteinase 3 (PR3) comprises a mutation that reduces or abolishes protease activity.21. The blood treatment device according to claim 16 , wherein the matrix comprises a support to which the monomeric form of proteinase 3 (PR3) is bound.22. The blood treatment device according to claim 16 , wherein the blood treatment device is an adsorption cartridge and is perfused with whole blood.23. The blood treatment device according to claim 16 , wherein the blood treatment device is located in an extracorporeal blood circuit through which the blood of ...

Regional decoagulation system for extracorporeal blood-circulation circuit

A system is described for the regional decoagulation of the blood in an extracorporeal circulation circuit comprising means for infusion of a solution of a citrate or citric acid on the main circuit, which are set upstream of the first filtration unit; for infusion of a solution for electrolyte restoration on the main circuit, which are set downstream of the filtration unit and a secondary circuit for recirculation of the plasma water obtained by the filtration unit. The secondary circuit comprises: a first cartridge comprising an anion-exchange resin charged with chlorine ions; a second cartridge comprising a cation-exchange resin charged with sodium and potassium ions, which is set downstream of the first cartridge and means for removal of a first fraction of the plasma water obtained by the filtration unit.

Extracorporeal removal of microvesicular particles

The invention described herein teaches methods of removing microvesicular particles, which include but are not limited to exosomes, from the systemic circulation of a subject in need thereof with the goal of reversing antigen-specific and antigen-nonspecific immune suppression. Said microvesicular particles could be generated by host cells that have been reprogrammed by neoplastic tissue, or the neoplastic tissue itself. Compositions of matter, medical devices, and novel utilities of existing medical devices are disclosed.

Method for removal of viruses from blood by lectin affinity hemodialysis

The present invention relates to a method for using lectins that bind to pathogens having high mannose surface glycoproteins or fragments thereof which contain high mannose glycoproteins, to remove them from infected blood or plasma in an extracorporeal setting. Accordingly, the present invention provides a method for reducing viral load in an individual comprising the steps of obtaining blood or plasma from the individual, passing the blood or plasma through a porous hollow fiber membrane wherein lectin molecules are immobilized within the porous exterior portion of the membrane, collecting pass-through blood or plasma and reinfusing the pass-through blood or plasma into the individual.

RENAL FAILURE THERAPY MACHINES AND METHODS INCLUDING CONVECTIVE AND DIFFUSIVE CLEARANCE

A renal failure therapy machine includes a blood cleaning filter, a sorbent device configured to regenerate used therapy fluid from the blood cleaning filter, a therapy fluid pump configured to pump regenerated therapy fluid from the sorbent device back to the blood cleaning filter, and a flow restrictor in fluid communication with the blood cleaning filter, the therapy fluid pump and the sorbent device, the flow restrictor configured to cause regenerated therapy fluid pumped by the therapy fluid pump from the sorbent device to the blood cleaning filter to be pressurized so that a first amount of the regenerated therapy fluid performs convective clearance and a second amount of the regenerated therapy fluid performs diffusive clearance. 1. A renal failure therapy machine comprising:a blood cleaning filter;a sorbent device configured to regenerate used therapy fluid from the blood cleaning filter;a therapy fluid pump configured to pump regenerated therapy fluid from the sorbent device back to the blood cleaning filter; anda flow restrictor in fluid communication with the blood cleaning filter, the therapy fluid pump and the sorbent device, the flow restrictor configured to cause regenerated therapy fluid pumped by the therapy fluid pump from the sorbent device to the blood cleaning filter to be pressurized so that a first amount of the regenerated therapy fluid performs convective clearance and a second amount of the regenerated therapy fluid performs diffusive clearance.2. The renal failure therapy machine of claim 1 , which operates the flow restrictor to cause the regenerated therapy fluid to be pressurized so that at least ten percent of the regenerated therapy fluid performs convective clearance and at least a substantial amount of remaining regenerated therapy fluid performs diffusive clearance.3. The renal failure therapy machine of claim 1 , wherein the sorbent device includes a sorbent cartridge downstream from the blood cleaning filter claim 1 , the sorbent ...

TARGETED APHERESIS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND IMMUNE DISORDERS

This invention uses “Targeted Apheresis” to treat patients with Rheumatoid Arthritis and other autoimmune and inflammatory disorders. “Targeted Apheresis” is a process whereby only the pathogenic and pro-inflammatory elements associated with the disease symptoms are simultaneously and selectively removed from the blood by passing the blood through an extracorporeal affinity device containing selective binding agents. Removal of these pathogenic and pro-inflammatory elements will ameliorate the symptoms of autoimmune disease and may prolong the period of disease remission. 1. A means of selectively removing pathological , pro-inflammatory and disease inciting factors from the blood of patients with rheumatoid arthritis and other autoimmune diseases using targeted apheresis.2. According to the targeted apheresis process for treating RA patients employs an extracorporeal affinity device containing two or more immobilized binding agents selected from the list of: “altered IgG” agarose beads claim 1 , “altered IgG” binding agent agarose beads; TNF-alpha binding agent agarose beads claim 1 , and IL-1 binding agent agarose beads.3. According to an affinity device composed of a chamber with an inlet and an outlet aperture and top and bottom filters containing within two or more layers of immobilized binding agents conjugated to agarose beads. Each layer is separated from the other by filters that allow through passage of plasma through the device. Each compartment contains a specific binding layer selected from the list of: “altered IgG” agarose beads claim 2 , “altered IgG” binding agent agarose beads; TNF-alpha binding agent agarose beads claim 2 , and IL-1 binding agent agarose beads.4. According to an affinity device composed of a chamber with an inlet and an outlet aperture and top and bottom filters containing within a single mixed bed of two or more different immobilized binding agents conjugated to agarose beads selected from the list of: “altered IgG” agarose beads ...

BONE BYPASS SHUNTS AND METHODS USING THEREOF

Bone bypass shunts and methods using thereof. Method for affecting a pathophysiological condition in a body of a live subject includes exemplary steps/procedures of: connecting an inlet port of a bone bypass shunt to a first bone portion adjacent a first bone marrow location such that inlet port lumen of inlet port facilitates fluid communication with blood accumulated or flowing at first blood marrow location; connecting outlet port of the bone bypass shunt to second bone portion adjacent second bone marrow location, such that outlet port lumen of outlet port facilitates fluid communication with bone marrow; a formed cavity, or/and bone marrow vasculature, located at second bone marrow location; via inlet port lumen, removing a chosen volume of blood from first bone marrow location; and via outlet port lumen, delivering chosen volume of blood to the second bone marrow location. 1. A method for affecting a pathophysiological condition in a body of a live subject , the method comprising:connecting an inlet port of a bone bypass shunt to a first bone portion adjacent a first bone marrow location such that an inlet port lumen of said inlet port facilitates fluid communication with blood accumulated or flowing at said first blood marrow location;connecting an outlet port of said bone bypass shunt to a second bone portion adjacent a second bone marrow location such that an outlet port lumen of said outlet port facilitates fluid communication with at least one of bone marrow, a formed cavity, and bone marrow vasculature, located at said second bone marrow location;via said inlet port lumen, removing a chosen volume of blood from said first bone marrow location; andvia said outlet port lumen, delivering at least part of said chosen volume of blood to said second bone marrow location.2. The method according to claim 1 , comprising choosing said first bone marrow location and said second bone marrow in a single bone.3. The method according to claim 1 , comprising choosing ...

Recirculating dialysate fluid circuit for blood measurement

A blood based solute monitoring system for measuring at least one blood solute species that has a first recirculation flow path in fluid communication with a dialyzer. The first recirculation flow path is configured to allow a fluid to recirculate through a dialyzer such that the concentration of at least one solute species in the fluid becomes equilibrated to the solute species concentration of the blood in a blood compartment of the dialyzer. The blood solute monitoring system has at least one sensor to measure a fluid characteristic.

Cartridge and method for increasing myocardial function

The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions that affect myocardial function and to related methods. The cartridge can be used in treating a subject with myocardial dysfunction, such as a subject with chronic heart failure and/or acute decompensated heart failure.

PLASMAPHERESIS DEVICE

A plasmapheresis device includes a column or other flow mechanism in which plasma lows following separation of the plasma from cellular components like blood cells, platelets and the like. The column includes a moiety, such as an antibody, which selectively binds to galectin-3. By removing galectin-3 from the blood stream of a mammal by at least 10%, improvements in the treatment of inflammation, suppression of the formation of fibroses, and a variety of cancer treatments can be effected or improved. The device provides tor multiple columns to remove a variety of elements but includes one which selectively removes galectin-3 from the blood flow. Other agents may be added to the plasma before recombination with the cellular components of the blood, and before returning the recombined flow to the patient. 115-. (canceled)16. A device for performing plasmapheresis , comprising:a first conduit through which blood drawn from a mammalian patient travels under the influence of a pump;a separator for separating cellular components of said blood from plasma;a column device through which said plasma flows, which said column device selectively removes a plasma component, wherein said plasma component is selected from the group consisting of a heavy metal, an autoantibody, a pesticide, a toxin, oxidized cholesterol, oxidized low density lipoprotein, a cytokine, an immunoglobulin, complement, C-reactive protein, a receptor for tumor necrosis factor α, a receptor for tumor transforming growth factor β, a receptor for nuclear factor kappa β, vascular endothelial growth factor, C-reactive protein, fibrinogen, galectin-1, galectin-3 and cytokine receptors to provide treated plasma;a second conduit which receives said treated plasma following passage in said column device and wherein said treated plasma is combined with blood cells separated in said separator prior to return to said mammalian patient;wherein said first and second conduits provide for continuous flow of said blood and ...

Apparatus and methods to remove toxins from blood by plasmapheresis

Devices and method are provided for removing toxins, including protein-bound toxins, from blood. The device includes a housing having a receiving space and at least one hollow fiber extending through at least a portion of the receiving space. The at least one hollow fiber is operable to receive the stream of blood. The device further includes a plurality of beads disposed within the receiving space and external to the at least one hollow fiber. The at least one hollow fiber includes a plurality of pores operable to retain the one or more cellular elements of the stream of blood within the hollow fiber and to allow the one or more plasma elements of the stream of blood to pass from the hollow fiber to the receiving space of the housing. Each of the plurality of beads is configured to receive a toxin molecule from the one or more plasma elements.

CARTRIDGE AND METHOD FOR INCREASING MYOCARDIAL FUNCTION

The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions that affect myocardial function and to related methods. The cartridge can be used in treating a subject with myocardial dysfunction, such as a subject with chronic heart failure and/or acute decompensated heart failure. 1. A method of treating a subject having or at risk of developing chronic heart failure , the method comprising:(a) extracorporeally sequestering activated leukocytes and/or activated platelets present in a body fluid of the subject in a cartridge comprising(i) a rigid housing defining an inner volume (IV), a fluid inlet port and a fluid outlet port, wherein the inner volume is in fluid flow communication with the fluid inlet port and the fluid outlet port, and{'sup': −1', '−1', '−1, '(ii) a solid support disposed within the housing and defining a fluid contacting surface with a surface area (SA) capable of sequestering activated leukocytes and/or activated platelets, if present in a body fluid entering the housing via the fluid inlet port, wherein the SA/IV ratio of the cartridge is greater than 80 cmor is in the range from 25 cmto 2,000 cm, and the body fluid is introduced into the housing via the fluid inlet port under conditions that permit sequestration of the activated leukocytes and/or activated platelets on the fluid contacting surface of the solid support; and'}(b) treating the sequestered leukocytes and/or platelets to inhibit release of a pro-inflammatory substance or to deactivate the leukocytes and/or platelets thereby to treat or prevent chronic heart failure.2. The method of claim 1 , wherein the SA/IV ratio of the cartridge provided in step (a) is greater than 80 cm.3. The method of claim 1 , wherein the SA/IV ratio of the cartridge provided in step (a) is greater than 150 cm.45.-. (canceled)6. The method of claim 1 , wherein the solid support is disposed within the housing at a packing density in the range from 20% ...

ALPHA CHAIN OF THE HIGH-AFFINITY IGE RECEPTOR (FCERIA)

Disclosed is an alpha chain of the human high-affinity IgE receptor (FceRIa), wherein the amino acid lysine at position 43 (K43) is exchanged with an amino acid selected from the group consisting of alanine, serine, tyrosine, isoleucine, leucine, asparagine, aspartic acid, methionine, phenylalanine, glutamic acid, threonine, glutamine, tryptophan, glycine, and valine, preferably alanine, glycine, serine or tyrosine, especially alanine. 1. An alpha chain of the human high-affinity IgE receptor (FceRIa) , wherein the amino acid lysine at position 43 (K43) is exchanged with an amino acid selected from the group consisting of alanine , serine , tyrosine , isoleucine , leucine , asparagine , aspartic acid , and glycine.2. The alpha chain according to claim 1 , having the amino acid sequence according to SEQ ID No. 1 claim 1 , wherein the amino acid lysine at position 43 (K43) is exchanged with an amino acid selected from the group consisting of alanine claim 1 , serine claim 1 , tyrosine claim 1 , isoleucine claim 1 , leucine claim 1 , asparagine claim 1 , aspartic acid claim 1 , and glycine.3. The alpha chain according to claim 1 , wherein a further amino acid is exchanged claim 1 , which is an amino acid selected from lysine at position 31 (K31) claim 1 , arginine at position 40 (R40) claim 1 , isoleucine at position 41 (I41) claim 1 , phenylalanine at position 42 (F42) claim 1 , glycine at position 44 (G44) claim 1 , glutamic acid at position 45 (E45) claim 1 , lysine at position 142 (K142) claim 1 , lysine at position 196 (K196) claim 1 , arginine at position 199 (R199) claim 1 , and lysine at position 201 (K201).4. The alpha chain according to claim 1 , wherein the FceRIa is immobilised on a solid surface.5. FceRI comprising an alpha chain claim 1 , a beta chain and two gamma chains connected by two disulfide bridges claim 1 , wherein the alpha chain is a modified alpha chain according to .6. A method of prevention and/or treatment of IgE mediated diseases claim 1 , ...

BIOMIMETIC POLYMERS FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES

Antiviral biomimetic polymers (ABPs) are disclosed that can be used to prevent and/or treat viral disease. The ABPs are discovered by a process involving high-throughput screening of polymer libraries using disease-relevant bioactive molecules as target molecules. ABPs can be nanoscale (termed nanoABPs) or larger. Methods are described for the preparation and use of ABPs as prophylactics and therapeutics (in vivo) and as preventative agents, for example, in personal protective equipment (ex vivo). ABPs can be used to prevent and treat viral diseases including those caused by Filoviridae. 126-. (canceled)27. A method of selecting a biomimetic , non-imprinted , non-biological polymer that has a specific binding specificity for a filamentous virus , the method comprising:(a) preparing a library of non-imprinted, non-biological polymers;(b) contacting said library with an aqueous solution containing a filamentous virus or a filamentous virus-like particle;(c) detecting binding of said virus or virus-like particle to a subset of polymers within said library with a specific binding; and(d) identifying at least one of the subset of polymers within said library which binds to said filamentous virus or virus-like particle with a specific binding specificity, thereby providing a biomimetic, non-imprinted non-biological polymer that has a specific binding specificity for a filamentous virus.28. The method of claim 27 , wherein the library of biomimetic claim 27 , non-imprinted claim 27 , non-biological polymers comprises at least 1000 different non-imprinted claim 27 , non-biological polymers.29. The method of claim 27 , wherein the library of non-imprinted claim 27 , non-biological polymers is arrayed on a microscope slide.30. The method of claim 27 , wherein the detecting is performed by immunoassay or chemical detection.31. The method of claim 27 , wherein the filamentous virus is a filovirus.32. The method of claim 27 , wherein the filamentous virus is a species of Ebola ...

Soluble HLA class II complexes and methods of production and uses thereof

The production of soluble HLA class II molecules, as well as methods of using the soluble HLA class II molecules so produced, are described herein. 1. A method of producing isolated , HLA class II trimolecular complexes , wherein the isolated , HLA class II trimolecular complexes comprise a soluble , glycosylated alpha chain , a soluble , glycosylated beta chain , and a non-covalently associated , endogenously produced peptide ligand , the method comprising the steps of:inserting a first isolated nucleic acid segment and a second isolated nucleic acid segment into a mammalian cell line, the first isolated nucleic acid segment encoding a soluble form of an alpha chain of a HLA class II molecule having a first domain of a super secondary structural motif attached thereto, and the second isolated nucleic acid segment encoding a soluble form of a beta chain of the HLA class II molecule having a second domain of the super secondary structural motif attached thereto, wherein the mammalian cell line is a non-human mammalian cell line or a human cell line that does not express endogenous HLA class II, and wherein the mammalian cell line comprises glycosylation mechanisms required for glycosylation of proteins produced therein and chaperone complexes required for peptide ligand loading into HLA class II molecules;culturing the recombinant mammalian cell line under conditions that allow for expression of the soluble class II alpha and beta chains, association of the soluble class II alpha and beta chains through the first and second domains of the super secondary structural motif, glycosylation of the soluble class II alpha and beta chains, and loading of an antigen binding groove formed from the soluble class II alpha and beta chains with an endogenously produced, non-covalently associated peptide ligand, thereby producing soluble class II trimolecular complexes; andisolating the soluble class II trimolecular complexes secreted from the recombinant mammalian cell line, ...

Blood Treatment Method Adapted to at Least Partially Eliminate the Carbon Dioxide Content and Related Device

A blood treatment method is described that is adapted to at least partially eliminate the carbon dioxide content of the type comprising a step of drawing a blood flow. Advantageously according to the invention, the method further comprises the steps of: acidifying the blood flow with transformation of the related blood bicarbonate content into gaseous carbon dioxide; and eliminating the gaseous carbon dioxide content by means of a pressure gradient. 1. A blood treatment device adapted to at least partially eliminate the carbon dioxide content comprising:at least one inlet terminal for inflow of a blood flow;an outlet terminal for outflow of a treated blood flow;at least one acidification stage and one gas exchanger inserted, in series with each other, between the inlet and outlet terminals, said gas exchanger eliminating the gaseous carbon dioxide content of said acidified blood flow from said acidification stage.2. The blood treatment device according to claim 1 , wherein said acidification stage is adapted to insert an acid load in said blood flow claim 1 , with obtainment of an acidified blood flow which is inserted into said gas exchanger claim 1 , which ventilates it.3. The blood treatment device according to claim 2 , further comprising a deacidification stage inserted downstream of said gas exchanger and adapted to supply said treated blood flow to said outlet terminal.4. The blood treatment device according to claim 3 , wherein said gas exchanger is a membrane oxygenator adapted to eliminate claim 3 , via pressure gradient claim 3 , the gaseous carbon dioxide content from said acidified blood flow and possibly to oxygenate it claim 3 , giving rise to a decarbonised and possibly oxygenated blood flow claim 3 , still acidified claim 3 , sent to said deacidification stage.5. The blood treatment device according to claim 4 , wherein said deacidification stage is adapted to remove said acid load by means of anion eliminations with inflow of a basic load to said ...

Methods for removing cytokines from blood with surface immobilized polysaccharides

The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non microporous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.

EXTRACORPOREAL PERFUSION APPARATUS

Embodiments of the invention relate to an extracorporeal perfusion apparatus comprising an extracorporeal blood circuit for conveying blood, a filtrate circuit for conveying blood plasma, and a controller, wherein the filtrate circuit is connected to the extracorporeal blood circuit by means of a filter, wherein the filter has a sieving coefficient of 5% for substances having a molar mass of 340,000 g/mol (relative molecular mass of 340 kDa), and wherein a depletion agent comprising a first carrier having a neutral, hydrophobic surface is arranged in the filtrate circuit, wherein the perfusion apparatus comprises a dispensing means for feeding an endotoxin-binding lipopeptide into the extracorporeal blood circuit, wherein the endotoxin-binding lipopeptide is selected from the group consisting of polymyxins, polymyxin derivatives, prodrugs thereof, and a combination thereof. 1. An extracorporeal perfusion apparatus comprising an extracorporeal blood circuit for conveying blood , a filtrate circuit for conveying blood plasma , and a controller ,wherein the filtrate circuit is connected to the extracorporeal blood circuit via a filter, wherein the filter has a sieving coefficient of 5% for substances having a molar mass of 340,000 g/mol (relative molecular mass of 340 kDa), andwherein a depletion agent comprising a first carrier having a neutral, hydrophobic surface is arranged in the filtrate circuit,wherein the extracorporeal perfusion apparatus comprises a dispenser configured to feed an endotoxin-binding lipopeptide into the extracorporeal blood circuit, wherein the endotoxin-binding lipopeptide is selected from the group consisting of polymyxins, polymyxin derivatives, prodrugs thereof, and a combination thereof.2. The extracorporeal perfusion apparatus according to claim 1 , wherein the endotoxin-binding lipopeptide is a polymyxin selected from the group consisting of polymyxin B claim 1 , Colistin claim 1 , and prodrugs thereof.3. The extracorporeal perfusion ...

Extracorporeal Fluidic Device for Collecting Circulating Tumor Cells and Method of Use Thereof

A device can be used to retain circulating tumor cells (CTCs). The device can include a cross-flow module with a retentate channel and a permeate channel. A filter in the cross-flow module can separate the retentate channel from the permeate channel. The filter can be constructed such that CTCs are retained in the retentate channel while other cells can pass through the filter into the permeate channel. A recirculation channel can direct a flow from an outlet of the retentate channel back to an inlet of the retentate channel to thereby concentrate CTCs in the retentate flow. 1. A device for retaining circulating tumor cells (CTCs) , comprising:a retentate channel;a permeate channel;a first filter separating the retentate channel from the permeate channel and constructed such that CTCs are retained in the retentate channel while other cells pass through the first filter to the permeate channel; anda recirculation channel that directs a flow from an outlet of the retentate channel to an inlet of the retentate channel.2. The device of claim 1 , wherein the recirculation channel further comprises a treatment element to collect or concentrate CTCs.3. The device of claim 1 , wherein the recirculation channel further comprises a recirculation pump.4. The device of claim 2 , wherein the treatment element comprises a second filter for separating CTCs from the retentate fluid.5. The device of claim 4 , wherein the second filter is constructed such that white blood cells in the retentate fluid can pass through the treatment element.6. The device of claim 4 , wherein the first filter and/or the second filter is provided with an anti-EPCAM antibody claim 4 , anti-EFGR antibody claim 4 , or other antibody capable of binding CTCs.7. The device of claim 2 , wherein the treatment element is configured to expose white blood cells to concentrated CTCs claim 2 , thereby bringing the CTCs and white blood cells in close contact with each other to stimulate a patient's immune system to ...

SYSTEMS AND METHODS FOR PRIMING HEMODIALYSIS USING MULTIPLE FLUID SOURCES

A hemodialysis system configured to purge air from a blood circuit comprising: a dialyzer; a dialysis fluid circuit operable with the dialyzer via dialysis fluid inlet and outlet lines; the blood circuit operable with the dialyzer and including an arterial line, a venous line, a blood pump operable with the arterial line upstream of the dialyzer, and a physiologically acceptable fluid source in fluid communication with the arterial line upstream of the blood pump; and an air purging scheme wherein, with the dialysis fluid inlet and outlet lines connected to the dialyzer, air is purged using dialysis fluid or other physiologically acceptable fluid pumped by at least one of the fresh or used dialysis fluid pumps from the dialysis fluid circuit, through the dialyzer, into the blood circuit, in combination with dialysis fluid or other physiologically acceptable fluid from the source introduced directly into the blood circuit. 1. A hemodialysis system configured to purge air from a blood circuit , the hemodialysis system comprising:a dialyzer; a fresh dialysis fluid pump,', 'a used dialysis fluid pump,', 'a first balancing unit including (i) a first fresh dialysis fluid chamber operable with the fresh dialysis fluid pump and (ii) a first used dialysis fluid chamber operable with the used dialysis fluid pump, and', 'a second balancing unit including (i) a second fresh dialysis fluid chamber operable with the fresh dialysis fluid pump and (ii) a second used dialysis fluid chamber operable with the used dialysis fluid pump;, 'a dialysis fluid circuit in fluid communication with the dialyzer via dialysis fluid inlet and outlet lines, the dialysis fluid circuit including'} an arterial line for removing blood from a patient and delivering the blood to the dialyzer,', 'a venous line for returning blood from the dialyzer to the patient,', 'a blood pump operable with the arterial line upstream of the dialyzer,', 'a physiologically acceptable fluid source in fluid communication ...

SYSTEM AND METHOD TO LYSE AND REMOVE RED BLOOD CELLS FROM A CELL PRODUCT

A method is provided for removing red blood cells from a suspension comprising red blood cells, white blood cells, platelets and plasma using a spinning membrane separator. The method comprises: a) flowing whole blood into the gap of the spinning membrane separator; b) collecting red blood cells and white blood cells in the gap and passing plasma and platelets through the membrane; c) introducing a first quantity of lysing buffer into the gap; d) incubating the red blood cells, white blood cells and lysing buffer in the gap for a period of time to cause a lysis reaction with the red blood cells; e) introducing a second quantity of lysing buffer into the gap to displace the first quantity of lysing buffer and a first quantity of red blood cell debris out of the gap; f) introducing a first quantity of wash buffer into the gap to quench the lysis reaction and displace the second quantity of lysing buffer and a second quantity of red blood cell debris out of the gap; and g) introducing a second quantity of wash buffer into the gap to flow washed white blood cells out of the housing. 1. A method for removing red blood cells from a suspension comprising red blood cells , white blood cells , platelets and plasma using a spinning membrane separator , the spinning membrane separator comprising a housing , a rotor rotatably supported within the housing , a membrane affixed to the rotor having a porous surface that permits plasma and platelets to pass therethrough but not red blood cells and white blood cells , with a gap being defined between the housing and the membrane , the method comprising:a) flowing whole blood into the gap;b) collecting red blood cells and white blood cells in the gap and passing plasma and platelets through the membrane;c) introducing a first quantity of lysing buffer into the gap;d) incubating the red blood cells, white blood cells and lysing buffer in the gap for a period of time to cause a lysis reaction with the red blood cells;e) introducing a ...

METHOD FOR REMOVAL OF VIRUSES FROM BLOOD BY LECTIN AFFINITY HEMODIALYSIS

The present invention relates to a method for using lectins that bind to pathogens having high mannose surface glycoproteins or fragments thereof which contain high mannose glycoproteins, to remove them from infected blood or plasma in an extracorporeal setting. Accordingly, the present invention provides a method for reducing viral load in an individual comprising the steps of obtaining blood or plasma from the individual, passing the blood or plasma through a porous hollow fiber membrane wherein lectin molecules are immobilized within the porous exterior portion of the membrane, collecting pass-through blood or plasma and reinfusing the pass-through blood or plasma into the individual. 168-. (canceled)69. A method of depleting high mannose glycoproteins from a sample , comprising:a) obtaining a sample comprising high mannose glycoproteins;b) passing the sample through a porous hollow fiber membrane, wherein a lectin is immobilized within a porous exterior portion of the porous hollow fiber membrane, and wherein the lectin binds to high mannose glycoproteins; andc) collecting the sample after (b).70. The method of claim 69 , wherein the sample is blood or plasma.71. The method of claim 70 , wherein the blood or plasma is obtained from an individual claim 70 , and further comprising reinfusing the pass-through blood or plasma into the individual.72Galanthus nivalisNarcissus pseudonarcissus. The method of claim 69 , wherein the lectin is selected from the group consisting of agglutinin (GNA) claim 69 , agglutinin (NPA) claim 69 , cyanovirin claim 69 , and Conconavalin A and mixtures thereof.73. The method of claim 72 , wherein the lectin is GNA.74. A method of isolating high mannose glycoproteins from a sample claim 72 , comprising:passing a sample comprising high mannose glycoproteins through a porous hollow fiber membrane, which comprises a lectin immobilized within a porous exterior portion of the porous hollow fiber membrane, wherein the lectin binds to the high ...

METHOD OF TREATING EXTRACELLULAR TISSUE AND VASCULAR CALCIFICATION AND ARTERIOSCLEROSIS

A novel therapy concept based on a removal of circulating BSP (bone sialoprotein) from the plasma of patients with chronic kidney disease (CKD) or highly at risk of developing arterial and vascular calcifications. The method comprises method of treatment of extracellular tissue and vascular calcifications, atherosclerosis, arteriosclerosis, and arterial calcification. The beneficial effects of this therapy have been proven by the observed correspondence between levels of circulating free BSP levels and mortality of CKD patients as well as in animal models. 1. A method of reducing arterial and vascular calcification or treating extracellular tissue and vascular calcification , atherosclerosis , arteriosclerosis , and arterial calcification comprising the administration of a therapeutically effective amount of a receptor molecule specifically binding to human bone-sialoprotein (BSP) in blood , plasma or serum.2. The method of claim 1 , wherein the receptor molecule is a human monoclonal antibody or a humanized monoclonal antibody recognizing an antigen determinant or epitope of BSP which is accessible in blood claim 1 , serum or plasma and bound by said monoclonal antibody whose sequence includes the six complementary determining regions (CDRs) fromthe antibody having the amino acid sequences set forth in SEQ ID NO: 4 and 5,the antibody having the amino acid sequences set forth in SEQ ID NO: 6 and 7, orthe antibody having the amino acid sequences set forth in SEQ ID NO: 8 and 9.3. The method of for treatment of aortic calcifications claim 1 , atherosclerotic intima lesions and artheriosclerotic intima/media lesions.4. The method of for reduced interstitial renal fibrosis and glomerolusclerosis and reduced media-to-lumen ratio of intrarenal vessels.5. The method of for obtaining reduced cardiac interstitial fibrosis and cardiac perivascular fibrosis.6. The method of for preventing vascular and arterial calcifications in patients with CKD and ESRD.7. The method of for ...

Bioartificial Liver

This document provides bioartificial liver (BAL) devices. Methods for making and using BAL devices also are provided. 1. A bioartificial liver device comprising a reservoir chamber configured to house hepatocyte spheroids, wherein said reservoir chamber comprises a mixing chamber and a settling volume chamber, wherein said mixing chamber is separated from said settling volume chamber by a funnel, and wherein said mixing chamber is in fluid communication with said settling volume chamber via at least one opening defined in said funnel. This application is a continuation of U.S. application Ser. No. 13/256,337 (now U.S. Pat. No. 10,130,748), filed Sep. 13, 2011, which is a National Stage application under 35 U.S.C. § 371 of International Application No. PCT/US2010/027203, filed Mar. 12, 2010, which claims the benefit of U.S. Provisional Application Ser. No. 61/160,150, filed on Mar. 13, 2009. The disclosures of the prior applications are considered part of (and are incorporated by reference in) the disclosure of this application.This invention was made with government support under DK56733 awarded by the National Institutes of Health. The government has certain rights in the invention.This document relates to bioartificial livers.According to the annual report of the American Liver Foundation in 2000, hepatitis and other liver diseases affect 25 million Americans. Liver failure is the 8th most frequent cause of death in the United States, accounting for roughly 43,000 deaths each year. Liver transplantation is currently the only effective treatment for medically refractory liver failure. Liver transplantation has some shortfalls, however, including a shortage of donor organs, restrictions on potential recipients, and side effects of drugs used to prevent rejection after transplantation. The problem of organ scarcity is demonstrated by the fact that nearly 2000 candidates for liver transplantation died on the waiting list in 2003. Over 500 of these patients were listed ...

Physical Removal Of Biological Agents Detected By A Magnecytometer

A system and method for analyzing a sample of liquid having an NMR signal in response to a magnetic field for the presence of an analyte. Included is an NMR device having a testing section that is adapted to contain a liquid and apply a magnetic field to the liquid. A complex comprised of a conjugate having a field gradient bound to the analyte that is of sufficient magnitude to quench the NMR signal of the liquid, when in the test section whereby the presence of the complex is determined by the absence of the NMR signal. The system and method also include a container having a binding agent therein that has an affinity for the analyte or foreign agent that is used to remove the foreign agent from a patient's blood or plasma. Blood or plasma is shunted through the container to remove or reduce the foreign agent by extracorporeal circulation. 1. A method of detecting and removing a foreign agent from blood or plasma , the method comprising the steps of:conjugating said foreign agent with a conjugate, said conjugate having a field gradient that quenches an NMR signal of a liquid to be tested for the presence of the foreign agent;placing said liquid in a sample testing section of a nuclear magnetic resonance device;applying a magnetic field to said liquid when said liquid is located in said sample testing section;testing said liquid for the presence of the foreign agent based upon said NMR signal of the liquid being quenched by said conjugate; andupon determining the presence of said foreign agent, removing said foreign agent from the blood or plasma by shunting the blood or plasma through a container having a binding agent therein, said binding agent having an affinity for the foreign agent that binds the foreign agent inside the container.2. The method of wherein said foreign agent is a cancer cell.3. The method of wherein said conjugate quenches the entire NMR signal of the liquid in said sample testing section.4. The method of wherein said sample test section has a ...

SYSTEMS OR APPARATUSES AND METHODS FOR PERFORMING DIALYSIS

The invention provides a method and an apparatus or system for dialysis. The method and apparatus or system are useful for removing an undesirable protein-binding substance such as a toxin from a biological fluid such as blood or blood plasma. As such, the method and apparatus or system are useful for treating a subject in need of dialysis such as a subject suffering from hepatic disease. The methods feature a) dialyzing a biological fluid against a dialysis fluid containing an adsorber for a protein-binding substance to be removed through a semipermeable membrane, b) adjusting the dialysis fluid so that the binding affinity of the adsorber for the protein-bound substance to be removed is lowered and the substance to be removed passes into solution, and c) balancing the volume or flow of one or more fluids in the apparatus or system suitable for dialyzing a biological fluid containing a protein-binding substance to be removed. The apparatus or system features a) a biological fluid circuit (); b) a dialysis fluid circuit (); c) a means () for solubilizing the protein-binding substance to be removed; d) a dialysis, filtration or diafiltration device (); e) a balancing system or apparatus suitable for balancing the volume or flow of one or more fluids in the apparatus or system suitable for dialyzing a biological fluid containing a protein-binding substance to be removed; and f) a dialysate regeneration unit. 1. A method for removing an unwanted substance from a biological fluid in an apparatus or a system suitable for dialyzing a biological fluid containing a protein-binding substance to be removed , comprisinga) dialyzing a biological fluid against a dialysis fluid containing an adsorber for a protein-binding substance to be removed through a semipermeable membrane,b) adjusting the dialysis fluid so that the binding affinity of the adsorber for the protein-bound substance to be removed is lowered and the substance to be removed passes into solution, andc) balancing ...

MEDICAMENT AND APPARATUS FOR TREATING CHRONIC KIDNEY DISEASE

The present invention provides a novel therapy concept based on a removal of circulation BSP (bone sialoprotein) from the plasma of patients with chronic kidney disease (CKD), preferably by plasmapheresis or an administration of antibodies against BSP in plasma. The present invention further provides a BSP absorber material for plasmapheresis and a pharmaceutical composition namely in form of anti-BSP antibodies for direct administration which are biocompatible in humans. The beneficial effects of this therapy have been proven by the observed correspondence between levels of circulating free BSP levels and mortality of CKD patients. 1. A medicament for treating extracellular tissue and vascular calcification , atherosclerosis , arteriosclerosis , and arterial calcification comprising an effective amount of a receptor molecule specifically binding to human bone-sialoprotein (BSP) in blood , plasma or serum.2. The medicament as claimed in claim 1 , wherein the receptor molecule is a human monoclonal antibody or a humanized monoclonal antibody or a rat monoclonal antibody4.3. The medicament as claimed in claim 2 , wherein the antibody comprises one or more functional portions of a protein sequence as disclosed in any of SEQ ID NO: 4 claim 2 , 5 claim 2 , 6 claim 2 , 7 claim 2 , 8 and 9.4. The medicament as claimed in claim 2 , wherein the receptor molecule or antibody comprises one or more of the functional complement determining regions (CDR) contained in any protein sequence of SED ID NO: 4 claim 2 , 5 claim 2 , 6 claim 2 , 7 claim 2 , 8 and 9.5. A medicament for treating extracellular tissue and vascular calcification as claimed in claim 1 , wherein the receptor molecule recognizes an antigen determinant or epitope of BSP which is accessible in plasma and bound by an antibody having any protein sequence of SEQ ID NO: 4 claim 1 , 5 claim 1 , 6 claim 1 , 7 claim 1 , 8 and 9.6. A receptor molecule or antibody as described in claim 2 , which is bound to or contained in ...

RENAL FAILURE THERAPY MACHINES AND METHODS INCLUDING CONVECTIVE AND DIFFUSIVE CLEARANCE

A renal failure therapy machine includes a blood cleaning filter, a dialysis fluid circuit including a balance chamber, the balance chamber including a fresh dialysis fluid compartment configured to send fresh dialysis fluid to the blood cleaning filter and a used dialysis fluid compartment configured to receive used dialysis fluid from the blood cleaning filter, a fresh dialysis fluid line in fluid communication with the fresh dialysis fluid compartment of the balance chamber and the blood cleaning filter, and a flow restrictor in fluid communication with the blood cleaning filter, the flow restrictor configured to cause fresh dialysis fluid delivered from the fresh dialysis fluid compartment, through the fresh dialysis fluid line, to the blood cleaning filter to be pressurized so that a first amount of the fresh dialysis fluid performs convective clearance and a second amount of the fresh dialysis fluid performs diffusive clearance. 1. A renal failure therapy machine comprising:a blood cleaning filter;a dialysis fluid circuit including a balance chamber, the balance chamber including a fresh dialysis fluid compartment configured to send fresh dialysis fluid to the blood cleaning filter and a used dialysis fluid compartment configured to receive used dialysis fluid from the blood cleaning filter;a fresh dialysis fluid line in fluid communication with the fresh dialysis fluid compartment of the balance chamber and the blood cleaning filter; anda flow restrictor in fluid communication with the blood cleaning filter, the flow restrictor configured to cause fresh dialysis fluid delivered from the fresh dialysis fluid compartment, through the fresh dialysis fluid line, to the blood cleaning filter to be pressurized so that a first amount of the fresh dialysis fluid performs convective clearance and a second amount of the fresh dialysis fluid performs diffusive clearance.2. The renal failure therapy machine of claim 1 , which operates the flow restrictor to cause the ...

SYSTEMS AND METHODS FOR CLOSED LOOP, REAL-TIME MODIFICATIONS OF PATIENT CELLS

Provided herein are bedside systems and methods for performing customized cell-based therapies and treatments in a patient-connected, closed-loop continuous-flow manner, including cellular modifications and treatments, e.g., to produce chimeric antigen receptor-T (CAR-T) cells among other cellular modifications and treatments. 163-. (canceled)64. A subject-connected , closed-loop system for the modification of a cell , the system comprising:a) an inlet conduit adapted for parenteral communication with the subject and adapted for receiving blood from the subject;b) a cell separation module in fluid communication with the inlet conduit, the cell separation module comprising a cell separator configured to produce a fraction enriched in a target nucleated blood cell type using the blood from the subject, and the cell separation module further comprising a first sampling unit for obtaining a sample of the fraction;c) a cell customization module in fluid communication with the cell separation module so as to receive the nucleated blood cell fraction enriched in the target cell type from the cell separation module, the cell customization module configured to present one or more modifying agents to the target nucleated blood cells, thereby generating modified cells, and the cell customization module further comprising a second sampling unit for obtaining a sample of the modified cells;d) a detector configured to conduct a detection operation and operably interfaced with the cell separation module, the cell customization module, operably interfaced between the cell separation module and the cell customization module, and/or operably interfaced between the cell customization module or the cell separation module and the subject;e) an outlet conduit adapted for parenteral communication with the subject and for conducting modified target cells parenterally to the subject; andf) a processor configured to control an operation of the inlet conduit, the cell separation module, the ...

Method and system to remove soluble tnfr1, tnfr2, and il2 in patients

A method, and system, to induce remission in diseases characterized by excess production of sTNR and interleukin 2 has been developed. In the most preferred embodiment, the system consists of antibodies to sTNFR1, sTNFR2 and sIL2R immobilized in a column containing a material such as SEPHAROSE™. The patient is connected to a pheresis machine which separates the blood into the plasma and red cells, and the plasma is circulated through the column until the desired reduction in levels of sTHFR1, sTNFR2, and IL2 achieved, preferably to less than normal levels. In the preferred method, patients are treated three times a week for four weeks. This process can be repeated after a period of time. Clinical studies showed reduction in tumor burden in patients having failed conventional chemotherapy and radiation treatments.

EXTRACORPOREAL CIRCUIT FOR REMOVAL OF CO2 FROM BLOOD

The present invention concerns an extracorporeal circuit for removing COfrom blood comprising a blood withdrawal line for withdrawing blood from the patient, a filtration unit for producing plasma water and a line for returning the blood to the patient, defining a main circuit; the extracorporeal circuit further comprises a decarbonating group comprising a secondary circuit for the recirculation of plasma water, means for removing a fraction of said plasma water, a COexchanger, a cationic resin charged with H+ ions set upstream of the COexchanger and adapted to generate acid plasma water, means for the infusion of the acid plasma water upstream of the COexchanger and means for the infusion of ions in a solution downstream of the COexchanger. 11100200300400500263054047123091093015309119aa. An extracorporeal circuit ( , , , , , ) for removing COfrom blood comprising a blood withdrawal line () for withdrawing blood from a patient , a filtration unit () for producing plasma water () and a line for returning the blood () to the patient , defining a main circuit (); said extracorporeal circuit being characterised in that it comprises a decarbonating group () comprising a secondary circuit () for recirculation of plasma water , means () for removing a fraction of said plasma water () , a COexchanger () , a cationic resin charged with H+ ions () set upstream of said COexchanger () and adapted to generate acid plasma water () , means () for infusion of said acid plasma water () upstream of said COexchanger () and means () for infusion of ions in a solution downstream of said COexchanger ().26. The extracorporeal circuit according to claim 1 , characterised in that said filtration unit () is a filter selected from the group consisting of a haemodialysis filter claim 1 , a haemofilter and a dialyser.3. The extracorporeal circuit according to claim 1 , characterised in that said cationic resin charged with H+ ions is selected from the group consisting of a cationic resin ...

BICARBONATE SENSOR FOR DIALYSIS

The invention relates to devices, systems, and methods for calculating a bicarbonate concentration in a fluid used in dialysis. The devices, systems, and methods can be used to calculate the bicarbonate concentration in either dialysate or blood. The invention measures the amount of carbon dioxide in both an acidified and non-acidified solution and calculates the bicarbonate concentration based on the difference in carbon dioxide concentrations. 1. A system , comprising:a flow path for use in dialysis;a first fluid line fluidly connected to the flow path;an acid source fluidly connected to the first fluid line;at least a first carbon dioxide sensor fluidly connected to the first fluid line; anda processor in communication with the first carbon dioxide sensor; the processor programmed to receive a measurement from the first carbon dioxide sensor of an amount of carbon dioxide in an acidified solution and in a non-acidified solution; and to calculate a total carbon dioxide and/or bicarbonate concentration in a fluid in the flow path based on the measured amount of carbon dioxide in the acidified solution and in the non-acidified solution.2. The system of claim 1 , further comprising a mixer fluidly connecting the flow path to the first fluid line claim 1 , the acid source fluidly connected to the mixer.3. The system of or claim 1 , further comprising a second carbon dioxide sensor; wherein the first carbon dioxide sensor measures the amount of carbon dioxide in the acidified solution; and wherein the second carbon dioxide sensor measures the amount of carbon dioxide in the non-acidified solution.4. The system of any of - claim 1 , wherein the flow path is a dialysate flow path.5. The system of claim 4 , wherein the first fluid line is upstream of a dialyzer claim 4 , and wherein the system measures the total carbon dioxide and/or bicarbonate concentration in fresh dialysate.6. The system of claim 4 , wherein the first fluid line is downstream of a dialyzer claim 4 , ...

RECIRCULATING FLUID FILTRATION SYSTEM

A fluid filtration system comprising a cross-flow filter is arranged to permit a first pump to recirculate part of the retentate of the filter to the inlet of the cross-flow filter and a second pump to return part of the permeate to the inlet of the cross-flow filter. A third pump is configured supply source fluid to the inlet of the filter. The flow path between the second pump and the cross-flow filter inlet may include an adsorption filter that may selectively remove contaminants, toxins, or pathogens in the permeate. A controller may control the first, second and third pumps to provide predetermined flow ratios among the fluid flow paths of the system in order to achieve a desired filtration level. This system may be applicable to the removal of harmful substances from blood, by first separating the plasma from the blood and then removing harmful substances from the plasma. 119.-. (canceled)20. A fluid filtration system comprising:a crossflow filter having a filter inlet, a retentate outlet, and one or more permeate outlets configured to provide a first stage filtration, the retentate outlet connected to the filter inlet via a first controllable pump and forming a recirculation path;the one or more permeate outlets of the crossflow filter connected to an adsorption filter inlet of an adsorption filter providing a second stage filtration, an adsorption filter outlet of the adsorption filter connected to the recirculation path and a filtration system outlet via a controllable valve; anda controller arranged to control the first pump and the valve;wherein the controller is configured to control the valve to direct at least a portion of an output flow of the adsorption filter to the recirculation path during operation of the filtration system.21. The system of claim 20 , further comprising a second controllable pump interposed between the one or more permeate outlets and the adsorption filter inlet claim 20 , wherein the controller is configured to control the ...

Cartridge and method for increasing myocardial function

The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions that affect myocardial function and to related methods. The cartridge can be used in treating a subject with myocardial dysfunction, such as a subject with chronic heart failure and/or acute decompensated heart failure.

Modular Extracorporeal Systems and Methods for Treating Blood-Borne Diseases

Extracorporeal systems and methods for treating blood-borne diseases in a subject or for developing drugs to treat blood-borne diseases include various environmental and treatment modules that can be tailored to a specific disease or infection. In certain embodiments of the systems and methods, a blood sample is treated with hydrostatic pressure, a pulsed electrical field, a pharmaceutical agent, microwave, centrifugation, sonification, radiation, or a combination thereof, under environmental conditions that are effective for the treatment.

MULTI-STAGED FILTRATION SYSTEM FOR BLOOD FLUID REMOVAL

A device includes (i) a housing defining an interior, wherein the interior has a blood compartment, a plasma compartment, and a fluid compartment; (ii) a first filter disposed in the interior of the housing, and (iii) a second filter disposed in the interior of the housing. The first filter separates at least a portion of the blood compartment from at least a portion of the plasma compartment. The first filter is configured to allow plasma components, but not cell components, of blood to pass through the first filter from the blood compartment to the plasma compartment. The second filter separates at least a portion of the plasma compartment from at least a portion of the fluid compartment. The second filter is configured to allow fluid and small molecules, but not larger components, to pass through the second filter from the plasma compartment to the fluid compartment. The device may include a sorbent in the plasma compartment to remove or reduce the concentration of selected components of the plasma. In embodiments, a system including the device includes a sorbent with which the plasma may be contacted. 1. A medical device comprising:a housing defining an interior, wherein the interior has a blood compartment, a plasma compartment, and a fluid compartment;a first filter disposed in the interior of the housing, wherein the first filter separates at least a portion of the blood compartment from at least a portion of the plasma compartment and wherein the first filter is configured to allow plasma components, but not cell components, of blood to pass through the first filter from the blood compartment to the plasma compartment;a second filter disposed in the interior of the housing, wherein the second filter separates at least a portion of the plasma compartment from at least a portion of the fluid compartment, and wherein the second filter is configured to allow fluid and small molecules less than 60,000 Da, but generally not larger components greater than 60,000 Da ...

AIRTRAP, SYSTEM AND METHOD FOR REMOVING MICROBUBBLES FROM A FLUID STREAM

An airtrap for a medical or physiological fluid in one embodiment includes a conical housing having a radius that increases from its top to its bottom when the housing is positioned for operation; a medical or physiological fluid inlet located at an upper portion of the conical housing; a medical or physiological fluid outlet located at a lower portion of the conical housing, the inlet and the outlet positioned and arranged so that medical or physiological fluid spirals in an increasing arc around an inside of the conical housing downwardly from the inlet to the outlet; and a gas collection area located at an upper portion of the conical housing. In another embodiment, the airtrap is shaped like a seahorse having a head section and a tail section. Any of the airtraps herein may be used for example in blood sets, peritoneal dialysis cassette tubing, and drug delivery sets. 1. An airtrap for a medical or physiological fluid comprising:a head section having (i) a largest diameter extending perpendicular to a plane bisecting the airtrap or (ii) a largest width and height extending perpendicular to the plane bisecting the airtrap;a medical or physiological fluid inlet provided by the head section;a tubular tail section, which when the airtrap is mounted for operation extends downwardly from the head section, the tubular tail section smaller in (a) diameter or (b) largest cross-sectional distance than (i) the largest diameter of the head section or (ii) the largest width or height of the head section, the tubular tail section including at least one smooth curve, jog and/or undulation positioned and arranged to cause fluid flowing from the head section, through the tubular tail section, to change direction at least one time; anda medical or physiological fluid outlet located at a distal end of the tubular section, beneath the medical or physiological fluid inlet when the airtrap is mounted for operation, such that air rises to a top of the head section via buoyancy, and ...

Recirculating Fluid Filtration System

A fluid filtration system comprising a cross-flow filter is arranged to permit a first pump to recirculate part of the retentate of the filter to the inlet of the cross-flow filter and a second pump to return part of the permeate to the inlet of the cross-flow filter. A third pump is configured supply source fluid to the inlet of the filter. The flow path between the second pump and the cross-flow filter inlet may include an adsorption filter that may selectively remove contaminants, toxins, or pathogens in the permeate. A controller may control the first, second and third pumps to provide predetermined flow ratios among the fluid flow paths of the system in order to achieve a desired filtration level. This system may be applicable to the removal of harmful substances from blood, by first separating the plasma from the blood and then removing harmful substances from the plasma.

GASLESS EXTRA-CORPOREAL CARBON DIOXIDE REMOVAL

A carbon dioxide absorption medium. The absorption medium includes a plurality of hollow fibers and a plurality of binder particles. The hollow fibers have walls comprising a selectively permeable membrane that is configured to permit passage of gaseous carbon dioxide but not liquids. The plurality bind particles are dispersed between the hollow fibers and comprise an absorbent material configured to absorb gaseous carbon dioxide and to bind the carbon dioxide in a solid state. 1. A carbon dioxide absorption medium comprising:a plurality of hollow fibers, each hollow fiber of the plurality having a proximal end, a distal end, a lumen extending between the proximal and distal ends, and a wall surrounding the lumen, the wall of each hollow fiber of the plurality comprising a membrane selectively permeable to gaseous carbon dioxide; anda plurality of binder particles dispersed between hollow fibers of the plurality, each binder particle of the plurality being configured to absorb gaseous carbon dioxide and bind the carbon dioxide in a solid state.2. The carbon dioxide absorption medium of claim 1 , wherein the membrane comprising the wall of each hollow fiber of the plurality comprises at least one polymer selected from the group consisting of cellulose acetate claim 1 , cellulose triacetate claim 1 , polyamide claim 1 , polysulfone claim 1 , polyethersulfone (PES) claim 1 , polyacrylonitrile (PAN) claim 1 , sulfonated polyacrylonitrile claim 1 , polymethylmethacrylate (PmmA) claim 1 , and polymethylpentene (PMP).3. The carbon dioxide absorption medium of claim 1 , wherein the wall of each hollow fiber of the plurality has an outer thickness ranging from about 5 μm to about 50 μm.4. The carbon dioxide absorption medium of claim 1 , wherein the binder particles of the plurality have a maximum dimension ranging from about 100 μm to about 10 claim 1 ,000 μm.5. The carbon dioxide absorption medium of claim 1 , wherein the plurality of binder particles comprise at least one ...

Liver support system

An artificial, extracorporeal system for liver replacement and/or assistance, comprises a liver dialysis device for conducting hemodialysis on a patient suffering from liver failure. The liver dialysis device comprises a first standard hollow fiber membrane dialyzer which does not allow passage of an essential amount of albumin over the membrane wall and which is perfused with the patient's blood, and a second hollow fiber membrane dialyzer which allows the passage of essential but defined amounts of albumin over the membrane wall and which receives the blood of the first standard hemodialyzer. The filtrate space is closed off from the lumen space of the hollow fibers and is populated by adsorbent material which may comprise one or more different adsorbents.

BLOOD FILTRATION CARTRIDGE END CAP

The invention relates to a removable cap for a blood filter cartridge useful in facilitating dispersal of whole blood in the cartridge. The cartridge has a removable cap on at least one and preferably both of its input and output ends. The caps comprise an annular flange means having attached thereto an outer annular wall and an annular inner wall. The annular inner wall defining a cavity covered by a conical, concave filter mesh. The end cap also comprises a channel means positioned under the cavity and a part of said flange means, for reception of any fluid which passes through said concave filter mesh. 1. An end cap for use in a blood filter device , comprising an annular flange means having attached thereto an outer annular wall and an annular inner wall , said annular inner wall defining a cavity , said cavity covered by a conical , concave filter mesh , said end cap further comprising a channel means positioned under said cavity and a part of said flange means , for reception of any fluid which passes through said concave filter mesh.2. The end cap of claim 1 , wherein said conical concave filter mesh is flexibly attached to said annular inner wall.3. The end cap of claim 2 , wherein said conical concave filter mesh has been flexibly attached to said inner wall via an adhesive claim 2 , solvent bonding claim 2 , ultrasonic bonding claim 2 , spin welding claim 2 , or insert molding.4. The end cap of claim claim 2 , wherein said outer annular wall comprises a ribbed configuration.5. The end cap of claim 1 , wherein said channel means comprises a luer.6. The end cap of claim 1 , further comprising a horizontal covering means which engages said cavity and said outer wall.7. The end cap of claim 1 , wherein said conical concave filter mesh comprises openings with a diameter of from about 5μ to about 150μ.8. The end cap of claim 7 , wherein said openings have a diameter of from about 50μ to about 100μ.9. The end cap of claim 1 , wherein said conical concave filter ...

Blood purifying filter and blood purifying apparatus having the same

Provided are a blood purifying filter and a blood purifying apparatus including the same. The blood purifying filter includes a plasma separation filter, a hemodialysis filter, a housing, and a plasma outlet. The plasma separation filter separates plasma from blood. The hemodialysis filter removes toxins and waste products from blood. The housing provides installation spaces for the plasma separation filter and the hemodialysis filter and defines a plasma flow section outside the plasma separation filter and the hemodialysis filter. The plasma outlet is provided at one side of the housing to allow plasma passing the plasma flow section to be discharged out of the blood purifying filter. 1. A blood purifying filter comprising:a plasma separation filter separating plasma from blood;a hemodialysis filter removing toxins and waste products from blood;a housing providing installation spaces for the plasma separation filter and the hemodialysis filter and defining a plasma flow section outside the plasma separation filter and the hemodialysis filter; anda plasma outlet provided at one side of the housing to allow plasma passing the plasma flow section to be discharged out of the blood purifying filter.2. The blood purifying filter of claim 1 , wherein:the plasma separation filter comprises a plasma separation filter housing having an internal space and a plasma separation membrane accommodated in the internal space of the plasma separation filter housing, the plasma separation membrane dividing the internal space of the plasma separation filter housing into a blood flow region and a plasma flow region;the hemodialysis filter comprises a hemodialysis filter housing having an internal space and a hemodialysis membrane accommodated in the internal space of the hemodialysis filter housing, the hemodialysis membrane dividing the internal space of the hemodialysis filter housing into a blood flow region and a dialysate flow region; andthe plasma separation filter housing has a ...

NANOCLAY SORBENT METHODS FOR USE WITH DIALYSIS

Dialysis is enhanced by using nanoclay sorbents to better absorb body wastes in a flow-through system. The nanoclay sorbents, using montmorillonite, bentonite, and other clays, absorb significantly more ammonium, phosphate, and creatinine, and the like, than conventional sorbents. The montmorillonite, the bentonite, and the other clays may be used in wearable systems, in which a dialysis fluid is circulated through a filter with the nanoclay sorbents. Waste products are absorbed by the montmorillonite, the bentonite, and the other clays and the dialysis fluid is recycled to a patient's peritoneum. Using an ion-exchange capability of the montmorillonite, the bentonite, and the other clays, waste ions in the dialysis fluid are replaced with desirable ions, such as calcium, magnesium, and bicarbonate. The nanoclay sorbents are also useful for refreshing a dialysis fluid used in hemodialysis and thus reducing a quantity of the dialysis fluid needed for the hemodialysis. 1. A method for refreshing used dialysis fluid , the method comprising:providing a filter with processed nanoclay particles having at least one dimension from about 1 nm to about 200 nm;flowing a used dialysis fluid through the filter so that the processed nanoclay absorbs waste product ions from the used dialysis fluid; andreplacing the waste product ions with ions from the processed nanoclay particles to refresh the dialysis fluid, wherein the refreshed dialysis fluid is capable of reuse as a dialysis fluid.2. The method of claim 1 , wherein the dialysis fluid is hemodialysis fluid.3. The method of claim 1 , wherein the filter used for refreshing the used dialysis fluid comprises hollow fibers claim 1 , and wherein the processed nanoclay particles are contained within a wall or a lumen of the hollow fibers.4. The method of claim 1 , wherein the ions from the processed nanoclay particles used for replacement are selected from the group consisting of: sodium claim 1 , calcium claim 1 , potassium claim 1 ...

NANOCLAY SORBENT METHODS FOR USE WITH DIALYSIS

Dialysis is enhanced by using nanoclay sorbents to better absorb body wastes in a flow-through system. The nanoclay sorbents, using montmorillonite, bentonite, and other clays, absorb significantly more ammonium, phosphate, and creatinine, and the like, than conventional sorbents. The montmorillonite, the bentonite, and the other clays may be used in wearable systems, in which a dialysis fluid is circulated through a filter with the nanoclay sorbents. Waste products are absorbed by the montmorillonite, the bentonite, and the other clays and the dialysis fluid is recycled to a patient's peritoneum. Using an ion-exchange capability of the montmorillonite, the bentonite, and the other clays, waste ions in the dialysis fluid are replaced with desirable ions, such as calcium, magnesium, and bicarbonate. The nanoclay sorbents are also useful for refreshing a dialysis fluid used in hemodialysis and thus reducing a quantity of the dialysis fluid needed for the hemodialysis. 1. A method of making hollow fibers , the method comprising:preparing a spinning solution of a polymer for a hollow fiber;preparing an infusing slurry of nanoparticles, a solvent used in the spinning solution and water;extruding the spinning solution through nozzles of a spinneret to form a hollow fiber;extruding the infusing slurry through a center of the spinneret into a lumen of the hollow fiber;placing the hollow fiber into a coagulation bath;gathering the hollow fiber, wherein the nanoparticles are located within the lumen of the hollow fiber; andat least partially drying the hollow fiber.2. The method of claim 1 , further comprising:cutting the hollow fiber into a plurality of lengths;forming a filter by potting ends of the plurality of lengths; andplacing the filter into a housing.3. The method of claim 1 , wherein the spinning solution comprises a hydrophobic polymer claim 1 , a hydrophilic polymer claim 1 , a solvent for the hydrophobic polymer and the hydrophilic polymer claim 1 , and a ...

METHOD AND DEVICE FOR PURIFICATION OF BLOOD FROM CIRCULATING CELL FREE DNA

The invention provides apheresis devices and their use for removal of substantially all types of cell free DNA (cfDNA) in patients' blood, including nucleosome-bound cfDNA, exosome-bound cfDNA and unbound cfDNA (including double stranded DNA (dsDNA), single stranded DNA (ssDNA) and oligonucleotides), to limit the negative effects of the circulating cfDNA and to treat various diseases. 1. A device configured to perform apheresis comprising one or more affinity matrices , wherein said one or more affinity matrices are capable of capturing nucleosome-bound cell free DNA (cfDNA) , exosome-bound cfDNA , and unbound cfDNA from blood or plasma of a subject.2. The device of claim 1 , wherein the unbound cfDNA comprises dsDNA claim 1 , ssDNA and oligonucleotides.3. The device of claim 1 , wherein the device comprises two or more affinity matrices.4. The device of claim 3 , wherein (i) the first one or more affinity matrices is capable of capturing nucleosome-bound cell free DNA (cfDNA) and/or exosome-bound cfDNA and (ii) the second one or more affinity matrices is capable of capturing unbound cfDNA claim 3 , and wherein the first and second affinity matrices are arranged within the device in any order.5. The device of claim 4 , wherein (i) the first one or more affinity matrices comprises a DNA binding protein claim 4 , an anti-histone antibody claim 4 , an anti-nucleosome antibody claim 4 , a DNA intercalating agent claim 4 , a DNA binding polymer claim 4 , an anti-DNA antibody claim 4 , a lectin claim 4 , or and any combination thereof claim 4 , and (ii) the second one or more affinity matrices comprises a DNA binding protein claim 4 , a DNA intercalating agent claim 4 , a DNA binding polymer claim 4 , an anti-DNA antibody claim 4 , or and any combination thereof.625.-. (canceled)26. The device of claim 1 , wherein the device comprises a single affinity matrix.27. (canceled)28. The device of claim 27 , wherein the histone is H1 histone.29. The device of claim 28 , wherein ...

METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS

The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same. 1. A method of making a population of immune effector cells (e.g. , T cells) that can be engineered to express a chimeric antigen receptor (CAR) , the method comprising:a) providing a frozen input sample comprising immune effector cells,b) thawing the frozen input sample, to produce a thawed sample, andc) performing elutriation on the thawed sample and collecting immune effector cells, thereby producing an output sample comprising immune effector cells that are suitable for expression of a CAR.2. The method of claim 1 , wherein:(i) the frozen input sample is a plasma apheresis sample; (1) at least 10%, 15%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 35%, or 40% monocytes;', '(2) less than 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, or 20% T cells; and/or', '(3) at least 1%, 2%, 5%, 10%, 15%, 20%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% B cells;, '(ii) the input sample comprises (1) less than 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 2%, 2%, 1%, 0.5%, 0.2%, or 0.1% monocytes;', '(2) at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% T cells;', '(3) less than 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 2%, 2%, 1%, 0.5%, 0.2%, or 0.1% B cells;', '(4) at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, or 99.9% CD4+CD25+ cells; and/or', '(5) at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, or 99.9% CD8+CD25+ cells; or, '(iii) the output sample comprises(iv) the method has a T cell yield recovery of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% T cells.3. The method of claim 1 , wherein: d) depleting CD19+ cells under flow conditions;', 'e) performing density centrifugation using a medium comprising iodixanol and ...

IMMUNOADSORPTION

Upon administration of rAAV vectors the humoral immune response (neutralizing antibodies) is the first barrier that needs to be overcome. Surprisingly it was found that by using immunoadsorption for depletion of immunoglobulins from the blood (plasma), subjects can be highly efficiently treated with rAAV vectors, i.e. obtain highly efficient transduction after rAAV vector administration, in spite of the presence of high levels of nAb. 120-. (canceled)21. A method of administering a recombinant adeno-associated virus (rAAV) to a subject , comprising:(a) selectively depleting a subject's circulating anti-AAV immunoglobulins by contacting the subject's blood with an extracorporeal device for immunoadsorption, the device comprising a binding moiety attached to a matrix, wherein the binding moiety selectively binds anti-AAV immunoglobulins, and(b) subsequently administering an rAAV to the subject.22. The method of claim 21 , wherein the binding moiety comprises at least one AAV epitope that is selectively bound by anti-AAV immunoglobulins.23. The method of claim 21 , wherein the binding moiety is selected from the group consisting of AAV capsids claim 21 , AAV VP1 claim 21 , AAV VP2 claim 21 , AAVP VP3 claim 21 , and AAV capsid peptides.24. The method of claim 22 , wherein the binding moiety is selected from the group consisting of AAV capsids claim 22 , AAV VP1 claim 22 , AAV VP2 claim 22 , AAVP VP3 claim 22 , and AAV capsid peptides.25. The method of claim 21 , wherein prior to depleting the subject's circulating immunoglobulins claim 21 , the subject had neutralizing antibodies that bind to a capsid of the rAAV as a result of previously receiving a treatment comprising a rAAV vector.26. The method of claim 21 , wherein the rAAV is administered intravenously.27. The method of claim 21 , wherein the amount of anti-AAV immunoglobulins in the subject's blood is depleted by at least 90%.28. The method of claim 21 , wherein the selective depletion step is performed at most ...

Method and device for treating cancer

A method and device treats cancer where blood from a cancer patient passes through an array of passageways within an interior of a chamber. The passageways include wells having porous membrane wall portions that enable a molecular-sized activating agent in a carrier fluid that enhances an immune response to pass through these porous wall portions. Pore size is such to allow the molecular-sized activating agent in the interior of the chamber to enter the wells yet prevents immune cells and cancer cells in the wells to pass through the porous wall portions into the interior of the chamber. Blood is retained in the wells so that it remains in contact with the immune cells and cancer cells for a predetermined period sufficient to enhance an immune response. Then the cells with an enhanced immune response are return to the patient. 1. A medical device comprisinga chamber with an inlet and an outlet in fluid communication with an interior of the chamber to enable a carrier fluid to flow in one direction into the inlet, through the interior of the chamber, and out the outlet, anda plurality of tubular passageways within the chamber, said passageways assembled within said interior and configured to be placed in fluid communication with said patient to enable blood from said patient to flow through the passageways in a direction opposite to said one direction,said tubular passageways having an interior wall with a plurality of wells therein having open mouths of predetermined dimensions that enable immune cells and cancer cells in a patient's blood flowing through the passageways to pass through the open mouths and enter the wells,said wells including a porous membrane wall with a predetermined average pore size that enables an activating agent introduced into the carrier fluid flowing through the interior of the chamber to pass through a well's porous membrane wall and enter said well yet prevents immune cells and cancer cells in a well to flow through said porous wall into ...

CLEANING OF BIOLOGICAL FLUID

The present invention relates to removal of protein bound deleterious substances from an extracorporeal biological fluid by changing the affinity of the substance to the protein. The invention relates to the use of displacer substances for removal of deleterious substances. The present invention also relate to a method of removal, a system, a cleaning fluid comprising the displacer substances for removal of deleterious substances. 1. A method of removing a deleterious substance bound to a protein in an extracorporeal biological fluid comprising:a) contacting a displacer substance with the biological fluid under conditions in which the displacer substance displaces deleterious substance bound to the protein; andb) removing the displaced deleterious substance from the biological fluid;{'sub': 5', '10, 'wherein the displacer substance is selected from C-C-fatty acid, or derivatives thereof, or salts thereof; and salicylic acid, derivatives thereof, or salts thereof; or combinations thereof.'}2. The method according to claim 1 , wherein the displacer substance is a C-C-fatty acid claim 1 , or derivatives thereof claim 1 , or salts thereof.3. The method according to claim 1 , wherein the displacer substance is salicylic acid claim 1 , derivatives thereof claim 1 , or salts thereof.4. The method according to claim 1 , wherein the deleterious substance comprises p-cresol claim 1 , p-cresyl sulfate claim 1 , indoxyl sulfate claim 1 , CMPF claim 1 , and combinations thereof.5. The method according to claim 1 , wherein the protein is albumin.6. The method according to claim 1 , wherein the extracorporeal biological fluid is selected from blood; blood plasma; or peritoneal fluid.7. The method according to claim 1 , wherein the displacer substance is a combination of C-C-fatty acids claim 1 , or derivatives thereof claim 1 , or salts thereof; and salicylic acid claim 1 , derivatives thereof.8. (canceled)9. A method of removing a deleterious substance bound to a protein in an ...

APPARATUS FOR REMOVING PROTEIN-BOUND TOXINS FROM BLOOD PLASMA

The invention relates to an apparatus for extracorporeal removal of protein-bound toxins from blood plasma comprising a first line device, a second line device, a third line device and a fourth line device, a dialyzer or hemofilter arranged between the first line device and the second line device and/or an adsorber, means for generating a field, at least partially surrounding the first line device and/or the dialyzer or hemofilter and/or the adsorber, a controllable fluid conveyance device arranged in the first line device and/or the second line device, and at least one controllable body fluid conveyance unit arranged in the third line device and/or the fourth line device, a filter, wherein the permeate side of the filter is connected to the first line device and the second line device, and the side of the filter to be dialyzed is connected at its inlet to the third line device, which can be connected to a patient and is connected at its outlet to the fourth line device which can be connected to the patient, wherein a controllable flow of fluid through the line devices and the dialyzer or hemofilter and/or the adsorber can be generated by means of the fluid conveyance devices. 110122427181012191410181916101216242720. An apparatus for extracorporeal removal of protein-bound toxins from blood plasma comprising a first line device () , a second line device () , a third line device () and a fourth line device () line device , a dialyzer or hemofilter () arranged between the first line device () and the second line device () and/or an adsorber () , means for generating a field () , at least partially surrounding the first line device () and/or the dialyzer or hemofilter () and/or the adsorber () , a controllable fluid conveyance device () arranged in the first line device () and/or the second line device () , and at least one controllable body fluid conveyance unit () arranged in the third line device () and/or the fourth line device () , a filter () ,{'b': 20', '10', ' ...

Carbon Block/Filtration Bed/Conical Reactor with Fluidized Bed System Allowing Small Sorbent Particles to Regenerate Fluid During Extracorporeal Blood Treatment

Methods and devices for powdered sorbent regeneration of biologic fluids are disclosed. The present invention includes three novel methods, which may be used singly or in any combination, for constraining or immobilizing powders so that they can be perfused with a biological fluid or dialysate: a porous carbon block filter, a filtration bed of very fine powder, and a cone-shaped reactor.

Manifold For Wearable Artificial Kidney

Flexible manifolds configured for use in a wearable artificial kidney are provided and can include an array of manifold plates defining one or more flow path and which are adapted to receive dialysis components including cleaning columns and dialyzers. Wearable artificial kidneys are also provided. For example, a wearable artificial kidney can include a flexible manifold, a first flow path, a second flow path, a third flow path, a first cleaning column, a first dialyzer, a second dialyzer, a second cleaning column, and at least one pump. Systems for performing dialysis are further provided. The systems can include a wearable artificial kidney and manifold inlet and outlet lines for connecting the peritoneum of a dialysis patient to the wearable artificial kidney. Methods for performing dialysis utilizing the flexible manifolds, wearable artificial kidneys, and systems containing the same, are also provided. 1. A flexible manifold configured for use as part of a wearable artificial kidney , the flexible manifold comprising: a first manifold plate comprising a first lateral edge, a first portal, and a first conduit in fluid communication with the first portal, and', 'a second manifold plate comprising a second lateral edge, a second portal, and a second conduit in fluid communication with the second portal, the first lateral edge positioned adjacent to the second lateral edge; and, 'an array of manifold plates comprising'}a first flexible hinge joining the first manifold plate and the second manifold plate at the first and second lateral edges, the first flexible hinge comprising a first flexible tube joining the first conduit and the second conduit to form a first flow path.2. The flexible manifold of claim 1 , wherein:the first manifold plate further comprises a third portal and a third conduit in fluid communication with the third portal;the second manifold plate further comprises a fourth portal and a fourth conduit in fluid communication with the fourth portal; ...

CLOSED-CIRCUIT DEVICE AND METHODS FOR ISOLATION, MODIFICATION, AND READMINISTRATION OF SPECIFIC CONSTITUENTS FROM A BIOLOGICAL FLUID SOURCE

The present invention relates to a method and apparatus for the isolation, modification and re-administration of a molecule or biomolecule, or a class of biomolecules, from the body fluid of a mammal via an extracorporeal closed circuit device. The device is able to capture and modify the biomolecule by the covalent or non-covalent attachment of a secondary molecule or protein, by cross-linking the captured molecule, or by altering the structure of the molecule (for example, by deglycosylation, peptide cleavage, or aggregation). The apparatus can be used to return the modified molecule or biomolecule to the mammalian subject. The device and methods may be utilized for the patient-specific diagnosis and/or treatment of a disease state which presents an associated molecule or protein in plasma or any other fluidized physiological system. 1. A method for enhancing the body fluid of a subject comprising:(a) conducting a body fluid from a mammalian subject into an extracorporeal closed circuit comprising (i) an inlet; said inlet being connected to (ii) a partitioning chamber comprising fractionation means which allows passage of a fluid fraction containing a targeted component of said body fluid while retaining other components of said body fluid, said partitioning chamber being connected to (iii) an outlet for returning said body fluid to said mammalian subject; and (iv) a sequestering chamber comprising a capture support capable of binding to or reacting with said targeted component upon contact with said fluid fraction; wherein said sequestering chamber is connected to said partitioning chamber so as to receive said fluid fraction from the partitioning chamber or to return the fluid fraction to the partitioning chamber;(b) conducting said fluid fraction into said sequestering chamber, whereby at least a portion of said targeted component in the fluid fraction is bound to or undergoes a modification reaction with said capture support;(c) optionally carrying out a ...

PLASMAPHERESIS DEVICE

A plasmapheresis device includes a column or other flow mechanism in which plasma flows following separation of the plasma from cellular components like blood cells, platelets and the like. The column includes a moiety, such as an antibody, which selectively binds to galectin-3. By removing galectin-3 from the blood stream of a mammal by at least 10%, improvements in the treatment of inflammation, suppression of the formation of fibroses, and a variety of cancer treatments can be effected or improved. The device provides for multiple columns to remove a variety of elements but includes one which selectively removes galectin-3 from the blood flow. Other agents may be added to the plasma before recombination with the cellular components of the blood, and before returning the recombined flow to the patient. 1. A device for performing plasmapheresis , comprising:a first conduit through which blood drawn from a mammalian patient travels under the influence of a pump;a separator for separating cellular components of said blood from plasma;a column device through which said plasma flows, which said column device selectively removes galectin-3 (gal-3) from said plasma to provide treated plasma;a second conduit which receives said treated plasma following passage in said column device and wherein said treated plasma is combined with blood cells separated in said separator prior to return to said patient;wherein said first and second conduits provide for substantially continuous flow of said blood and plasma from said patient and return to said mammalian patient.2. The device of claim 1 , wherein said device comprises at least one additional column device claim 1 , for removal of a plasma component other than gal-3.3. The device of claim 1 , wherein said device comprises at least one port through which a therapeutic agent can be added to said treated plasma claim 1 , separated blood claim 1 , or both prior to return to said patient.4. The device of claim 1 , wherein said ...

PLASMA OR SERUM PRODUCTION AND REMOVAL OF FLUIDS UNDER REDUCED PRESSURE

In some embodiments, the present invention generally relates to the separation of blood within a device to form plasma or serum. In some embodiments, the present invention generally relates to the removal of fluids, such as blood, contained within a device. In one aspect, the present invention is generally directed to systems and methods for receiving blood from a subject and processing the blood to form plasma or serum. For example, a device may be applied to the skin of a subject to receive blood from the subject and pass the blood through a separation membrane, which separates the blood into plasma and a portion concentrated in blood cells. As another example, blood or plasma may be allowed to clot within the device and serum (the unclotted portion of the blood) may be withdrawn from the device. The device may contain, in some cases, a vacuum source such as a pre-packaged vacuum to facilitate receiving of blood and/or passage of the blood through the separation membrane to produce plasma or serum. In certain embodiments, plasma, serum, or other fluids may be removed from the device by inserting a needle into a portion of the device that has reduced pressure, expelling gas into the device through the needle, then receiving plasma, serum, or other fluids through the needle. 1177-. (canceled)178. A device for receiving bodily fluid from a subject , the device comprising:an inlet for introduction of a bodily fluid from the subject into the device;a storage chamber;a first membrane that is substantially impermeable to cells, wherein the first membrane separates the inlet from the storage chamber;a second membrane that is gas permeable but is substantially liquid impermeable;a vacuum chamber having a pressure less than ambient pressure; anda seal that can be manipulated to control a fluid communication pathway between the vacuum chamber and the storage chamber.179. The device of claim 178 , wherein the second membrane is substantially hydrophobic.180. The device of ...

Process and Device for Depleting a Targeted Substance and Use Thereof

This invention is directed to a process for depleting one or more targeted substances such as toxins, proteins such as one or more immune checkpoint inhibitors (ICI), or a combination thereof from a subject. Immune checkpoint inhibitors (ICI), such as PD-1 protein, PD-1 ligand (PD-L1), CTLA-4, LAG-3, TIM3 and others are known to be involved in inhibition of T-cell activation in tumor patients. This invention is also directed to a device for depleting ICI such as PD-1 protein, PD-1 ligand (PD-L1) including soluble PD-L1 (sPD-L1), PD-L2, CTLA-4 including soluble form sCTLA-4, LAG-3, TIM3, or toxins from a subject. This invention is further directed to the use of the process and the devices for treating medical conditions such as cancers, other diseases and substance overdose. 1. A process for depleting at least one target substance from a body fluid of a subject , said process comprising the steps of:directing said body fluid of said subject into a capturing device, wherein said body fluid contains said target substance, and wherein said capturing device comprises an affinity matrix comprising an immobile phase and at least one affinity agent affixed to said immobile phase, said affinity agent is configured to bind to said target substance; andpassing said body fluid through said affinity matrix for said affinity agent to bind and immobilize said target substance to said immobile phase, producing a processed body fluid having at least a portion of said target substance depleted therefrom.2. The process of claim 1 , wherein said affinity agent comprises a biological affinity agent claim 1 , a chemical affinity agent claim 1 , a physical affinity agent claim 1 , or a combination thereof claim 1 , wherein said biological affinity agent comprises a protein claim 1 , an antibody claim 1 , a binding fragment of an antibody claim 1 , an antigen claim 1 , a fragment of an antigen claim 1 , a neoantigen polypeptide comprising one or more neoantigens or epitopes claim 1 , an ...

FILTER DEVICE COMBINING BEADS AND FIBERS

A filter apparatus, a method for the manufacture of the filter apparatus, the use of the filter apparatus in medical, chemical and/or biotechnological applications, and an apparatus for use in the manufacture of the filter apparatus. The filter apparatus has a cylindrical housing and a plurality of hollow fibers. The hollow fibers are combined to form a bundle in the housing and are embedded and held in each case at the end sides in a molding compound. The filtrate space is filled with particles of a chemically or physically active substance. 1. A hollow fiber membrane module for the treatment of fluids , comprising(a) a cylindrical filter housing;(b) a bundle of essentially parallel hollow fiber membranes distributed longitudinally within the housing, wherein the open ends are in fluid communication with a distribution space and with a collection space, and wherein the ends are embedded in a sealing compound such that the open ends of the hollow fibers extend through the sealing compound;(c) a filtrate space, which is closed off from the distribution space and the collection space and the lumen space of the hollow fiber membranes and which is optionally interconnected with an inlet means and/or an outlet means;(d) an inlet means for feeding the fluid into one of the filtrate space and the distribution space which is in fluid communication with the lumen side of the hollow fiber membranes, the filtrate space being optionally interconnected with one of the inlet means and an outlet means;(e) a first outlet means for removing the treated fluid from the housing, said first outlet means being in fluid communication with the collection space, and optionally a second outlet means for removing treated fluid from the filtrate space;wherein the filtrate space is homogenously populated with a particulate material being capable of interacting with at least one component of the fluid with a filling ratio of between 0.6 and 1.0.2. A module according to claim 1 , wherein the ...

Sorbent cartridge to measure solute concentrations

A sorbent based monitoring system for measuring the solute concentration of at least one component of a fluid. The system has a sorbent regeneration system for regeneration of the fluid and has a sorbent cartridge that has at least one material layer. The fluid is conveyed through the sorbent cartridge and contacts at least one sensor after having contacted at least one material layer.

EXTRACORPOREAL PERFUSION APPARATUS

Embodiments of the invention relate to an extracorporeal perfusion apparatus comprising an extracorporeal blood circuit for conveying blood, a filtrate circuit for conveying blood plasma, and a controller, wherein the filtrate circuit is connected to the extracorporeal blood circuit by means of a filter, wherein the filter has a sieving coefficient of 5% for substances having a molar mass of 340,000 g/mol (relative molecular mass of 340 kDa), and wherein a depletion agent comprising a first carrier having a neutral, hydrophobic surface is arranged in the filtrate circuit, wherein the perfusion apparatus comprises a dispensing means for feeding an endotoxin-binding lipopeptide into the extracorporeal blood circuit, wherein the endotoxin-binding lipopeptide is selected from the group consisting of polymyxins, polymyxin derivatives, prodrugs thereof, and a combination thereof.

Methods for removing cytokines from blood with surface immobilized polysaccharides

The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.

Bilayer 2d material laminates for highly selective and ultra-high throughput filtration

Various examples are provided for highly selective and ultra-high throughput filtration using bilayer two-dimensional (2D) material laminates and highly absorptive medium of 2D material laminates or solution dispersions. In one example, a 2D material bilayer membrane includes a first membrane layer; an interlinking layer of interlinking molecules disposed on the first membrane layer; and a second membrane layer disposed on the interlinking layer. The interlinking molecules electrostatically or covalently interlink the second membrane layer and first membrane layer.

OPEN SURFACE GRAPHITIC MATERIALS FOR ADSORPTION OF CYTOKINES FROM BLOOD

The present disclosure is directed to methods of removing proteins, including cytokines, from blood and blood products, the methods comprising contacting the blood or blood product with a form of carbon having high graphitic contents and slit-shaped mesopores and macropores, the pore size dimensions chosen to be comparable to the size of the proteins, wherein the contacting results in the removal of high levels of the protein from the blood or blood product in minutes or hours. 1. A method of removing proteins or peptides from blood or a blood product , the method comprising contacting the blood or blood product with a carbon form having slit-shaped mesopores and macropores , the pore size dimensions chosen to be comparable to the size of the proteins or peptides , wherein the contacting results in the removal of at least 80% of the protein or the peptide from the blood or blood product in less than 120 minutes.2. The method of claim 1 , wherein the carbon form comprises thermally expanded graphite (TEG).3. The method of claim 1 , wherein the carbon form comprises graphene nanoplatelets (GNPs).4. The method of claim 1 , wherein the carbon form comprises polymer derived ceramic carbide-derived carbon (PDC-CDC).5. The method of claim 1 , wherein the protein or the peptide has a molecular weight in a range of from 5 to 60 kDa.6. The method of claim 1 , wherein the protein/peptide is a cytokine.7. The method of claim 6 , wherein the cytokine is a chemokine claim 6 , interferon claim 6 , interleukin claim 6 , lymphokine claim 6 , or tumour necrosis factor8. The method of claim 1 , wherein the protein is IL-6 claim 1 , IL-8 claim 1 , or TNF-α claim 1 , lymphotoxin-α (aka TNF-β).9. The method of claim 1 , wherein at least 80% of the protein or the peptide is removed from the blood or blood product in less than 60 minutes.10. The method of claim 1 , wherein the carbon form is dispersed within a polymer composite.11. The method of wherein the GNPs are vacuum annealed C-500 ...

A METHOD FOR PREPARING A GROWTH FACTORS CONTAINING PLATELET RELEASATE

The present invention relates to a method for preparing a growth-factors containing platelet releasate from a fluid mammalian platelet concentrate, comprising the consecutive steps of subjecting the platelet concentrate to a pathogen reduction step to disrupt non-enveloped viruses; subjecting the platelet concentrate to an activation step to cause the platelets to release growth factors; recovering a fibrinogen depleted fluid platelet releasate; subjecting the fibrinogen depleted fluid platelet releasate to a second pathogen concentration reduction step to disrupt enveloped viruses; subjecting the platelet releasate to sterile filtering and recovering a filtrate liquid containing the growth factors. 1. A method for preparing a growth-factors containing platelet releasate from a fluid mammalian platelet concentrate , comprising the consecutive steps ofa. subjecting the platelet concentrate to a first pathogen concentration reduction step with the purpose of disrupting both DNA and RNA of micro-organisms present in the platelet concentrate;b. subjecting the platelet concentrate to an activation step by contacting it with an activating agent, with the purpose of causing the platelets to release at least part of alpha granules and growth factors present therein, thereby providing a fluid platelets releasate;c. subjecting the fluid platelet releasate to a fibrinogen concentration reduction step and recovering a fibrinogen depleted fluid platelet releasate;d. subjecting the fibrinogen depleted fluid platelet releasate to a second pathogen concentration reduction step with the purpose of disrupting enveloped viruses;e. subjecting the platelet releasate to sterile filtering and recovering from the filtering step a filtrate liquid containing the growth factors,f. dividing the filtrate liquid into individual portions, wherein the volume of the individual portion is adjusted such that each portion contains approximately the same number of platelets,g. subjecting the thus ...

SORBENT CARTRIDGE CONFIGURATIONS FOR IMPROVED DIALYSATE REGENERATION

A regeneration system that has a first regeneration module containing a first chosen regenerative substance; a second regeneration module containing the first chosen regenerative substance; and a first mixing chamber. A first outlet stream of a fluid sequentially exits the first mixing chamber, flows through the first regeneration module in fluid communication with the first chosen regenerative substance and returns to the first mixing chamber, and a second outlet stream of the fluid sequentially exits the first mixing chamber and flows through the second regeneration module in fluid communication with the first chosen regenerative substance. 1. A regeneration system , comprising:a first regeneration module containing a first regenerative substance;a second regeneration module containing the first regenerative substance; anda first mixing chamber, wherein a first outlet stream of a fluid sequentially exits the first mixing chamber, flows through the first regeneration module in fluid communication with the first regenerative substance and returns to the first mixing chamber, and a second outlet stream of the fluid sequentially exits the first mixing chamber and flows through the second regeneration module in fluid communication with the first regenerative substance; wherein the first regenerative substance removes at least one anionic waste species from the fluid.2. The system of claim 1 , wherein the at least one anion waste species comprises phosphate anions.3. The system of claim 1 , wherein the first regenerative substance is either zirconium oxide or activated alumina.4. The system of claim 1 , wherein the first regeneration module further comprises at least a second regenerative substance capable of converting urea to ammonium ions.5. The system of claim 1 , wherein the second regeneration module further comprises at least a second regenerative substance capable of converting urea to ammonium ions.6. The system of claim 4 , wherein the second regenerative ...

MULTI-STAGE BLOOD PURIFICATION APPARATUS FOR REMOVAL OF TOXINS

The present invention relates to a multi-stage blood purification apparatus designed to remove substances from a bodily fluid of a subject. In one aspect, the present invention relates to a sorbent stage containing a sorbent material by which a substance, or substances, is removed from a bodily fluid when in contact with the bodily fluid. In another aspect, the present invention provides a multi-stage blood purification apparatus containing a sorbent stage and a membrane stage. Further, methods of purifying a bodily fluid utilizing apparatuses of the present disclosure are provide.

PLASMA OR SERUM PRODUCTION AND REMOVAL OF FLUIDS UNDER REDUCED PRESSURE

In some embodiments, the present invention generally relates to the separation of blood within a device to form plasma or serum. In some embodiments, the present invention generally relates to the removal of fluids, such as blood, contained within a device. In one aspect, the present invention is generally directed to systems and methods for receiving blood from a subject and processing the blood to form plasma or serum. For example, a device may be applied to the skin of a subject to receive blood from the subject and pass the blood through a separation membrane, which separates the blood into plasma and a portion concentrated in blood cells. As another example, blood or plasma may be allowed to clot within the device and serum (the unclotted portion of the blood) may be withdrawn from the device. The device may contain, in some cases, a vacuum source such as a pre-packaged vacuum to facilitate receiving of blood and/or passage of the blood through the separation membrane to produce plasma or serum. In certain embodiments, plasma, serum, or other fluids may be removed from the device by inserting a needle into a portion of the device that has reduced pressure, expelling gas into the device through the needle, then receiving plasma, serum, or other fluids through the needle. 1177-. (canceled)178. A device for receiving blood from a subject and processing the blood to form plasma or serum , the device comprising:an inlet for introduction of blood from the subject into the device;a microfluidic channel for receiving fluid in fluid communication with the inlet;a storage chamber for receiving plasma or serum; anda membrane that is substantially impermeable to cells, wherein the membrane separates the microfluidic channel from the storage chamber and is capable of separating blood passing through to produce a portion enriched in plasma or serum.179. The device of claim 178 , wherein the storage chamber has a pressure less than ambient pressure.180. The device of claim ...

EXTRACORPOREAL DRUG REMOVAL FOR INTRAVASCULAR TRIGGERED DRUG DELIVERY SYSTEMS

A system for reducing toxicity from intravascular triggered drug delivery includes a chamber comprising an inflow port, an outflow port, and a filter positioned upstream of the outflow port. A trigger module is configured to trigger the release of a drug from an intravascular triggered drug delivery system present in blood in the chamber. A method for reducing toxicity from intravascular triggered drug delivery includes the steps of removing blood comprising an intravascular triggered drug delivery system from a patient's vascular system and delivering the blood to a chamber, applying a trigger to the blood to release a drug from the intravascular triggered drug delivery system, filtering the drug from the blood, and returning the filtered blood to the patient. 1. A system for reducing toxicity from intravascular triggered drug delivery comprising:a chamber comprising an inflow port, an outflow port, and a filter positioned upstream of the outflow port; anda trigger module configured to trigger the release of a drug from an intravascular triggered drug delivery system present in blood in the chamber.2. The system of claim 1 , wherein the trigger module comprises a heat source.3. The system of claim 1 , wherein the trigger module comprises a ultrasound source.4. The system of claim 1 , wherein the trigger module comprises a laser source.5. The system of claim 1 , wherein the trigger module comprises a light source.6. The system of claim 1 , wherein the trigger comprises a biological signal.7. The system of comprising:a first fluorescence light source and sensor disposed upstream of the inflow port and a second fluorescence light source and sensor disposed downstream of the outflow port.8. The system of claim 1 , wherein the filter is a carbon haemoperfusion filter.9. The system of claim 1 , wherein the filter is a charcoal filter.10. The system of further comprising:a first light source configured at a specified wavelength or spectrum to excite fluorescence or cause ...